Volume 55, No. 1

February 15, 2006

EDITORIAL

1 Quantifying Risks: The Case Between Glucocorticoids and Tuberculosis

Loreto Carmona

► See article, page 19

SPECIAL ARTICLES

3 Introduction to Special Section: Drug Evaluation in the United States, Canada, and the European Union

Edward H. Yelin and Patricia P. Katz

4 A Food and Drug Administration Primer

Lee S. Simon

9 Approval Process and Access to Prescription Drugs in Canada

Carlo A. Marra, Larry D. Lynd, Aslam H. Anis, and John M. Esdaile

12 Drug Evaluation and Approval Process in the European Union

M. Teresa San Miguel and Emilio Vargas

CLINICAL ASPECTS OF MOLECULAR RESEARCH

15 The Role of RANK Ligand in Normal and Pathologic Bone Remodeling and the Therapeutic Potential of Novel Inhibitory Molecules in Musculoskeletal Diseases

Stanley Cohen

ORIGINAL ARTICLES

Therapeutic Agents

19 Glucocorticoid Use, Other Associated Factors, and the Risk of Tuberculosis

Susan S. Jick, Eric S. Lieberman, Mahboob U. Rahman, and Hyon K. Choi

- ► See editorial, page 1
- 27 Retrospective Analysis of Utilization Patterns and Cost Implications of Coxibs Among Seniors in Quebec, Canada: What is the Potential Impact of the Withdrawal of Rofecoxib?

Elham Rahme, Elke Hunsche, Youssef Toubouti, and Isabelle Chabot

35 Prescription Opioid Use Among Older Adults With Arthritis or Low Back Pain Daniel H. Solomon, Jerry Avorn, Philip S. Wang, George Vaillant, Danielle Cabral, Helen Mogun, and Til Stürmer

Rheumatoid Arthritis

42 Effectiveness of the Primary Therapist Model for Rheumatoid Arthritis Rehabilitation: A Randomized Controlled Trial

Linda C. Li, Aileen M. Davis, Sydney C. Lineker, Peter C. Coyte, and Claire Bombardier

53 Synovial Fluid Levels of Anti-Cyclic Citrullinated Peptide Antibodies and IgA Rheumatoid Factor in Rheumatoid Arthritis, Psoriatic Arthritis, and Osteoarthritis

Dan Caspi, Marina Anouk, Itzhak Golan, Daphna Paran, Ilana Kaufman, Irena Wigler, David Levartovsky, Irena Litinsky, and Ori Elkayam

57 A Randomized Controlled Trial of Deep Water Running: Clinical Effectiveness of Aquatic Exercise to Treat Fibromyalgia

Marcos Renato Assis, Luciana Eduardo Silva, Adriana Martins Barros Alves, Ana Paula Pessanha, Valéria Valim, Daniel Feldman, Turíbio Leite de Barros Neto, and Jamil Natour

66 Exercise in Waist-High Warm Water Decreases Pain and Improves Health-Related Quality of Life and Strength in the Lower Extremities in Women With Fibromyalgia

N. Gusi, P. Tomas-Carus, A. Häkkinen, K. Häkkinen, and A. Ortega-Alonso

Systemic Lupus Erythematosus

74 Short-Term Prediction of Mortality in Patients With Systemic Lupus Erythematosus: Classification of Outcomes Using Random Forests

Michael M. Ward, Sinisa Pajevic, Jonathan Dreyfuss, and James D. Malley

Pediatric Rheumatology

81 Treatment of Pain in Juvenile Idiopathic Arthritis: A Survey of Pediatric Rheumatologists

Yukiko Kimura, Gary A. Walco, Etan Sugarman, Paola M. Conte, and Laura E. Schanberg

Psychosocial Issues

86 Illness Uncertainty, Partner Caregiver Burden and Support, and Relationship Satisfaction in Fibromyalgia and Osteoarthritis Patients

John W. Reich, Maureen E. Olmsted, and Christina M. van Puymbroeck

94 Determinants of Self Efficacy for Physical Tasks in People With Knee Osteoarthritis Monica R. Maly, Patrick A. Costigan, and Sandra J. Olney

Monica R. Mary, Farrick M. Costigan, and Sandra J. C

Disability

102 Profile of Arthritis Disability: II

Lois M. Verbrugge and Lucia Juarez

Inflammatory Myopathies

114 Functional Index-2: Validity and Reliability of a Disease-Specific Measure of Impairment in Patients With Polymyositis and Dermatomyositis

Helene Alexanderson, Lisbet Broman, Anna Tollbäck, Annika Josefson, Ingrid E. Lundberg, and Christina H. Stenström

Etiologic Studies of Autoimmunity

123 Lack of Detection of Human Retrovirus-5 Proviral DNA in Synovial Tissue and Blood Specimens From Individuals With Rheumatoid Arthritis or Osteoarthritis

Kerryl E. Piper, Arlen D. Hanssen, David G. Lewallen, Eric L. Matteson, Douglas R. Osmon, Mary C. Duffy, Rochelle A. Hagan, James M. Steckelberg, and Robin Patel

126 Chronic Periaortitis and HLA-DRB1*03: Another Clue to an Autoimmune Origin

Davide Martorana, Augusto Vaglio, Paolo Greco, Adele Zanetti, Gabriella Moroni, Carlo Salvarani, Mario Savi, Carlo Buzio, and Tauro M. Neri

Giant Cell Arteritis

131 Repetitive ¹⁸F-Fluorodeoxyglucose Positron Emission Tomography in Giant Cell Arteritis: A Prospective Study in 35 Patients

> Daniël Blockmans, Liesbet de Ceuninck, Steven Vanderschueren, Daniël Knockaert, Luc Mortelmans, and Herman Bobbaers

CONTRIBUTIONS FROM THE FIELD

- 138 Scleroderma Treatment Differs Between Experts and General Rheumatologists
 Janet E. Pope, Janine M. Ouimet, and Adriana Krizova
- 146 Thromboembolic Events as a Complication of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis

Sven Weidner, Syrus Hafezi-Rachti, and Harald D. Rupprecht

150 Effect of Anti-Tumor Necrosis Factor α Therapy on the Progression of Subclinical Atherosclerosis in Severe Rheumatoid Arthritis

Carlos Gonzalez-Juanatey, Javier Llorca, Carlos Garcia-Porrua, Javier Martin, and Miguel A. Gonzalez-Gay

CASE REPORTS

154 Pregnancy-Related Polymyositis and Massive Perivillous Fibrin Deposition in the Placenta: Are They Pathogenetically Related?

Noelyn Anne Hung, Christopher Jackson, Martha Nicholson, and John Highton

157 Pulmonary Fibrosis in a Patient With Rheumatoid Arthritis Treated With Adalimumab

Abraham Schoe, Nicole E. van der Laan-Baalbergen, Tom W. J. Huizinga, Ferdinand C. Breedveld, and Jacob M. van Laar

160 Sustained Spontaneous Clinical Remission in Giant Cell Arteritis: Report of Two Cases With Long-Term Followup

José Hernández-Rodríguez, Ana García-Martínez, Georgina Espígol-Frigolé, Josep M. Grau, Antonio Collado, and Maria C. Cid

163 Infliximab-Related Lupus and Associated Valvulitis: A Case Report and Review of the Literature

Tina Chadha and Jesus Edward Hernandez

TRAINEE ROUNDS

167 Churg-Strauss Syndrome Presenting With Salivary Gland Enlargement and Respiratory Distress

Francesco Boin, James J. Sciubba and John H. Stone

170 Submissions Invited for Themed Issue of Arthritis Care & Research: Disparities in Rheumatic Diseases

Volume 55, No. 2

April 15, 2006

171 Introduction to Special Section: Rheumatic Disease Through the Lifespan
Edward H. Yelin and Patricia P. Katz

EDITORIALS

172 Psychologically Meaningful Activity, Illness Intrusiveness, and Quality of Life in Rheumatic Diseases

Gerald M. Devins

▶ See article, page 224

175 Aging, Arthritis, and Disability

Kenneth Covinsky

► See article, page 248

SPECIAL ARTICLES: RHEUMATIC DISEASE THROUGH THE LIFESPAN

177 Level of Agreement Between Children, Parents, and Physicians in Rating Pain Intensity in Juvenile Idiopathic Arthritis

Pablo Garcia-Munitis, Marcia Bandeira, Angela Pistorio, Silvia Magni-Manzoni, Nicolino Ruperto, Ambra Schivo, Alberto Martini, and Angelo Ravelli

184 Cost of Treatment of Childhood-Onset Systemic Lupus Erythematosus

Hermine I. Brunner, Tina M. Sherrard, and Marisa S. Klein-Gitelman

189 Growing Up and Moving On in Rheumatology: Parents as Proxies of Adolescents With Juvenile Idiopathic Arthritis

K. L. Shaw, T. R. Southwood, and J. E. McDonagh, on Behalf of the British Society of Paediatric and Adolescent Rheumatology, Children's Chronic Arthritis Association, Lady Hoare Trust for Physically Disabled Children, and Arthritis Care

199 Health-Related Quality of Life in Adolescents With Juvenile Idiopathic Arthritis

K. L. Shaw, T. R. Southwood, C. M. Duffy, and J. E. McDonagh, on Behalf of the British Society of Paediatric and Adolescent Rheumatology, Children's Chronic Arthritis Association, Lady Hoare Trust for Physically Disabled Children, and Arthritis Care

208 Care of the Adult With Juvenile Rheumatoid Arthritis

Peter A. Nigrovic and Patience H. White

217 Childbearing Decisions and Family Size Among Women With Rheumatoid Arthritis

Patricia P. Katz

224 Illness Intrusion and Psychological Adjustment to Rheumatic Diseases: A Social Identity Framework

Ana F. Abraído-Lanza and Tracey A. Revenson

► See editorial, page 172

233 Reexamining the Arthritis-Employment Interface: Perceptions of Arthritis-Work Spillover Among Employed Adults

Monique A. M. Gignac, Deborah Sutton, and Elizabeth M. Badley

241 Quality of Osteoarthritis Care for Community-Dwelling Older Adults

David A. Ganz, John T. Chang, Carol P. Roth, Min Guan, Caren J. Kamberg, Fang Niu, David B. Reuben, Paul G. Shekelle, Neil S. Wenger, and Catherine H. MacLean

248 Population Impact of Arthritis on Disability in Older Adults

Jing Song, Rowland W. Chang, and Dorothy D. Dunlop

► See editorial, 175

256 Transitions to Mobility Difficulty Associated With Lower Extremity
Osteoarthritis in High Functioning Older Women: Longitudinal Data From the
Women's Health and Aging Study II

Shari M. Ling, Qian Li Xue, Eleanor M. Simonsick, Jing Tian, Karen Bandeen-Roche, Linda P. Fried, and Joan M. Bathon

- 264 Correlates of Knee Pain in Older Adults: Tasmanian Older Adult Cohort Study Guangju Zhai, Leigh Blizzard, Velandai Srikanth, Changhai Ding, Helen Cooley, Flavia Cicuttini, and Graeme Jones
- 272 How "Bad" Does the Pain Have to Be? A Qualitative Study Examining
 Adherence to Pain Medication in Older Adults With Osteoarthritis

 Joanna E. M. Sale, Monique Gignac, and Gillian Hawker

ORIGINAL ARTICLES

Rheumatoid Arthritis

279 Different Patterns of Illness-Related Interaction in Couples Coping With Rheumatoid Arthritis

Cindy Mann and Paul Dieppe

287 Effect of Etanercept on Fatigue in Patients With Recent or Established Rheumatoid Arthritis

Larry W. Moreland, Mark C. Genovese, Reiko Sato, and Amitabh Singh

- 294 Extent of Occupational Hand Use Among Persons With Rheumatoid Arthritis Saralynn Allaire, Frederick Wolfe, Jingbo Niu, Nancy Baker, Kaleb Michaud, and Michael LaValley
- 300 What Factors Account for Referral Delays for Patients With Suspected Rheumatoid Arthritis?

Lisa G. Suter, Liana Fraenkel, and Eric S. Holmboe

Osteoarthritis

306 Is There an Alternative to the Full-Leg Radiograph for Determining Knee Joint Alignment in Osteoarthritis?

Rana S. Hinman, Rachel L. May, and Kay M. Crossley

Total Joint Replacement

314 Expectations of Recovery From Revision Knee Replacement

Viji Venkataramanan, Monique A. Gignac, Nizar N. Mahomed, and Aileen M. Davis

CLINICAL ASPECTS OF MOLECULAR RESEARCH

322 Inhibition of T Cell Costimulation: An Emerging Therapeutic Strategy for Autoimmune Rheumatic Diseases

David I. Daikh, JoAnn Gillis, and David Wofsy

REVIEW ARTICLE

325 Catastrophizing and Pain in Arthritis, Fibromyalgia, and Other Rheumatic Diseases

Robert R. Edwards, Clifton O. Bingham III, Joan Bathon, and Jennifer A. Haythornthwaite

CONTRIBUTION FROM THE FIELD

333 Tumor Necrosis Factor Inhibitor Therapy and Risk of Serious Postoperative Orthopedic Infection in Rheumatoid Arthritis

Jon T. Giles, Susan J. Bartlett, Allan C. Gelber, Shikha Nanda, Kevin Fontaine, Victoria Ruffing, and Joan M. Bathon

337 Proposing Criteria Sets to the American College of Rheumatology

LETTERS

338 Cost-Effectiveness of Nonsteroidal Antiinflammatory Drug Strategies: Comment on the Article by Spiegel et al

Michael Loyd, Philip Jacobs, and Dale Rublee

339 Reply

Brennan M. R. Spiegel, Chiun-Fang Chiou, and Joshua J. Ofman

340 Etanercept-Induced Granulomas: Comment on the Article by Phillips and Weinblatt

Osvaldo Hübscher

340 Reply

Michael E. Weinblatt and Kristine Phillips

341 A Rheumatologist's Perspective on Musculoskeletal Ultrasound in Rheumatology: Comment on the Editorial by Roemer et al

David Kane, George Bruyn, Erin Arnold, and Walter Grassi

342 Radiologic Perspective on Musculoskeletal Ultrasound: Comment on the Editorial by Roemer et al

Ralf G. Thiele and Amy M. Evangelisto

343 Why Should Rheumatologists Perform Ultrasound? Comment on the Editorial by Roemer et al

Herbert B. Lindsley

343 Reply

Frank W. Roemer, Marnix van Holsbeeck, and Harry K. Genant

344 Submissions Invited for Themed Issue of Arthritis Care & Research: Disparities in Rheumatic Diseases

Volume 55, No. 3

June 15, 2006

EDITORIALS

345 Journal Policies on Authorship and Disclosures

Patricia P. Katz, Edward H. Yelin, and Michael D. Lockshin

348 Development of Classification and Response Criteria for Rheumatic Diseases

Classification and Response Criteria Subcommittee of the American College of Rheumatology Committee on Quality Measures

►See article, page 355

POLICY MATTERS

353 Mandating Coverage of Biologic Therapies for Rheumatic Disease: Where Evidence and Politics Meet

Yali A. Bair, Richard H. White, and Richard L. Kravitz

SPECIAL ARTICLE

355 The Pediatric Rheumatology International Trials Organization/American College of Rheumatology Provisional Criteria for the Evaluation of Response to Therapy in Juvenile Systemic Lupus Erythematosus: Prospective Validation of the Definition of Improvement

Nicolino Ruperto, Angelo Ravelli, Sheila Oliveira, Maria Alessio, Dimitrina Mihaylova, Srdjan Pasic, Elisabetta Cortis, Maria Apaz, Ruben Burgos-Vargas, Florence Kanakoudi-Tsakalidou, Ximena Norambuena, Fabrizia Corona, Valeria Gerloni, Stefan Hagelberg, Amita Aggarwal, Pavla Dolezalova, Claudia Magalhaes Saad, Sang-Cheol Bae, Richard Vesely, Tadej Avcin, Helen Foster, Carolina Duarte, Troels Herlin, Gerd Horneff, Loredana Lepore, Marion van Rossum, Lucia Trail, Angela Pistorio, Boel Andersson-Gäre, Edward H. Giannini, and Alberto Martini, for the Pediatric Rheumatology International Trials Organization (PRINTO) and the Pediatric Rheumatology Collaborative Study Group (PRCSG)

See editorial, page 348

ORIGINAL ARTICLES

Pediatric Rheumatology

364 Pilot Study of Fitness Training and Exercise Testing in Polyarticular Childhood Arthritis

D. Singh-Grewal, V. Wright, O. Bar-Or, and B. M. Feldman

373 Development of a Tool for Early Referral of Children and Adolescents With Signs and Symptoms Suggestive of Chronic Arthropathy to Pediatric Rheumatology Centers

Claudio Arnaldo Len, Maria Teresa Terreri, Rosana F. Puccini, Rudolf Wechsler, Edina Koga Silva, Leda M. Oliveira, Cássia M. Passarelli Barbosa, Glaura César Pedroso, and Maria Odete E. Hilário

378 Differences in Disease Outcomes Between Medicaid and Privately Insured Children: Possible Health Disparities in Juvenile Rheumatoid Arthritis

Hermine I. Brunner, Janalee Taylor, Maria T. Britto, Melinda S. Corcoran, Sandy L. Kramer, Paula G. Melson, Uma R. Kotagal, T. Brent Graham, and Murray H. Passo

Delivery of Health Care

385 Trust in Physicians and Elements of the Medical Interaction in Patients With Rheumatoid Arthritis and Systemic Lupus Erythematosus

Javier P. Berrios-Rivera, Richard L. Street, Jr, Maria G. Garcia Popa-Lisseanu, Michael A. Kallen, Marsha N. Richardson, Namieta M. Janssen, Donald M. Marcus, John D. Reveille, Noranna B. Warner, and Maria E. Suarez-Almazor

394 Rheumatology Care: Involvement in Medical Decisions, Received Information, Satisfaction With Care, and Unmet Health Care Needs in Patients With Rheumatoid Arthritis and Ankylosing Spondylitis

Ingvild Kjeken, Hanne Dagfinrud, Petter Mowinckel, Till Uhlig, Tore K. Kvien, and Arnstein Finset

402 Primary Therapist Model for Patients Referred for Rheumatoid Arthritis Rehabilitation: A Cost-Effectiveness Analysis

Linda C. Li, Andreas Maetzel, Aileen M. Davis, Sydney C. Lineker, Claire Bombardier, and Peter C. Coyte

411 Staging Joint Pain and Disability: A Brief Method Using Persistence and Global Severity

George Peat, Elaine Thomas, and Peter Croft

420 Population-Based Assessment of Adverse Events Associated With Long-Term Glucocorticoid Use

Jeffrey R. Curtis, Andrew O. Westfall, Jeroan Allison, Johannes W. Bijlsma, Allison Freeman, Varghese George, Stacey H. Kovac, Claire M. Spettell, and Kenneth G. Saag

Systemic Lupus Erythematosus

427 Influence of Coping Skills on Health-Related Quality of Life in Patients With Systemic Lupus Erythematosus

Silvana Rinaldi, Marta Ghisi, Luca Iaccarino, Sandra Zampieri, Anna Ghirardello, Piercarlo Sarzi-Puttini, Lucia Ronconi, Giulia Perini, Silvano Todesco, Ezio Sanavio, and Andrea Doria

434 Use of Computerized Assessment to Predict Neuropsychological Functioning and Emotional Distress in Patients With Systemic Lupus Erythematosus

Tresa M. Roebuck-Spencer, Cheryl Yarboro, Miroslawa Nowak, Kazuki Takada, Geneva Jacobs, Larissa Lapteva, Thomas Weickert, Bruce Volpe, Betty Diamond, Gabor Illei, and Joseph Bleiberg

Disability and Quality of Life

442 Health Status, Activity Limitations, and Disability in Work and Housework Among Latinos and Non-Latinos With Arthritis: An Analysis of National Data Ana F. Abraído-Lanza, Kellee White, Adria N. Armbrister, and Bruce G. Link

451 Quality of Life and Psychological Status in Patients With Primary Sjögren's Syndrome and Sicca Symptoms Without Autoimmune Features

Julien Champey, Emmanuelle Corruble, Jacques-Eric Gottenberg, Catherine Buhl, Tania Meyer, Céline Caudmont, Elisabeth Bergé, Jacques Pellet, Patrick Hardy, and Xavier Mariette

Self-Management Intervention

458 Change of Perspective: A Measurable and Desired Outcome of Chronic Disease Self-Management Intervention Programs That Violates the Premise of Preintervention/Postintervention Assessment

Richard H. Osborne, Melanie Hawkins, and Mirjam A. G. Sprangers

466 Changing Spectrum of the Diffuse Infiltrative Lymphocytosis Syndrome Dhiman Basu, Francis M. Williams, Chul W. Ahn, and John D. Reveille

Systemic Sclerosis

473 Influence of Clinical Features on the Health Status of Patients With Limited Cutaneous Systemic Sclerosis

Angela E. Gliddon, Caroline J. Doré, Peter J. Maddison, and the QUINS Trial Study Group

REVIEW ARTICLES

480 Psychometric Evaluation of Osteoarthritis Questionnaires: A Systematic Review of the Literature

Cindy Veenhof, Johannes W. J. Bijlsma, Cornelia H. M. van den Ende, Gabriella M. van Dijk, Martijn F. Pisters, and Joost Dekker

493 Osteoarthritis and Therapy

Zigang Ge, Yang Hu, Boon Chin Heng, Zheng Yang, Hongwei Ouyang, Eng Hin Lee, and Tong Cao

CASE REPORTS

501 Fulminating Hydralazine-Induced Lupus Pneumonitis

Belinda Birnbaum, Gurdip S. Sidhu, Robert L. Smith, Michael H. Pillinger, and Clement E. Tagoe

507 Collagenous Colitis and Spondylarthropathy

Javier Narváez, Nuria Montala, Noemi Busquets-Pérez, Joan M. Nolla, and José Valverde

LETTERS

513 Opioid Usage Among Older Adults With Low Back Pain: Comment on the Article by Solomon et al

Molly T. Vogt, Terence W. Starz, and C. Kent Kwoh

513 Reply

Daniel H. Solomon, Jerry Avorn, Philip S. Wang, George Vaillant, Danielle Cabral, Helen Mogun, and Til Stürmer

514 Submissions Invited for Themed Issue of Arthritis Care & Research: Disparities in Rheumatic Diseases

Volume 55, No. 4

August 15, 2006

EDITORIALS

515 What Are We Trying To Do?

Paul Dieppe

►See article, page 526

518 Polymyalgia Rheumatica: The Mess We Are Now In and What We Need to Do About It

Bhaskar Dasgupta, Andrew Hutchings, and Eric L. Matteson

CLINICAL ASPECTS OF MOLECULAR RESEARCH

521 Stem Cells and Rheumatology: Update on Adult Stem Cell Therapy in Autoimmune Diseases

Alan Tyndall and Kararina LeBlanc

ORIGINAL ARTICLES

Patient Reported Outcomes

Feeling Good Rather Than Feeling Better Matters More to Patients 526

Florence Tubach, Maxime Dougados, Bruno Falissard, Gabriel Baron, Isabelle Logeart, and Philippe Ravaud ▶See editorial, page 515

Therapeutics

Antirheumatic Drug Use and the Risk of Acute Myocardial Infarction 531 Samy Suissa, Sasha Bernatsky, and Marie Hudson

Channeling and Prevalence of Cardiovascular Contraindications in Users of 537 Cyclooxygenase 2 Selective Nonsteroidal Antiinflammatory Drugs

Georgio Mosis, Theo Stijnen, Jordi Castellsague, Jeanne P. Dieleman, Johan van der Lei, Bruno H. C. Stricker, and Miriam C. J. M. Sturkenboom

Assessment of Coxib Utilization By Rheumatologists for Nonsteroidal 543 **Antiinflammatory Drug Gastroprotection Prior to the Coxib Market** Withdrawals

Jeffrey D. Greenberg, Clifton O. Bingham III, Steven B. Abramson, George Reed, Mitsumasa Kishimoto, Kim Hinkle, and Joel Kremer, for the CORRONA

In Vivo and In Vitro Characterization of Skeletal Muscle Metabolism in 551 **Patients With Statin-Induced Adverse Effects**

S. Guis, D. Figarella-Branger, J. P. Mattei, F. Nicoli, Y. Le Fur, G. Kozak-Ribbens, J. F. Pellissier, P. J. Cozzone, N. Amabile, and D. Bendahan

Pediatric Rheumatology

Comparison Between Children With Juvenile Idiopathic Arthritis and Their **Parents Concerning Perceived Treatment Adherence**

Karine Toupin April, Debbie Ehrmann Feldman, Robert W. Platt, and Ciarán M. Duffy

564 Study of Subcutaneous Fat in Children With Juvenile Dermatomyositis

Sumit Verma, Surjit Singh, Anil Kumar Bhalla, and Madhu Khullar

Ankylosing Spondylitis

Infliximab Improves Productivity and Reduces Workday Loss in Patients With 569 Ankylosing Spondylitis: Results From a Randomized, Placebo-Controlled Trial

Désirée van der Heijde, Chenglong Han, Kirt DeVlam, Gerd Burmester, Filip van den Bosch, Paul Williamson, Mohan Bala, John Han, and Jürgen Braun

575 Development and Validation of the Edmonton Ankylosing Spondylitis **Metrology Index**

Walter P. Maksymowych, Cathy Mallon, Rhonda Richardson, Barbara Conner-Spady, Edwin Jauregui, Cecilia Chung, Lisa Zappala, Kevin Pile, and Anthony S. Russell

Joint Replacement

583 **Evaluating Quality of Life in Hip and Knee Replacement: Psychometric** Properties of the World Health Organization Quality of Life Short Version Instrument

Ilana N. Ackerman, Stephen E. Graves, Kim L. Bennell, and Richard H. Osborne

591 Trends in the Epidemiology of Total Shoulder Arthroplasty in the United States From 1990-2000

Nitin B. Jain, Laurence D. Higgins, Ulrich Guller, Ricardo Pietrobon, and Jeffrey N. Katz

Scleroderma

598 Scleroderma Lung: Initial Forced Vital Capacity as Predictor of Pulmonary Function Decline

Sotiris C. Plastiras, Stylianos P. Karadimitrakis, Panayiotis D. Ziakas, Panayiotis G. Vlachoyiannopoulos, Haralampos M. Moutsopoulos, and George E. Tzelepis

603 Durometry for the Assessment of Skin Disease in Systemic Sclerosis

Eugene Y. Kissin, Aileen M. Schiller, Rondi B. Gelbard, Jennifer J. Anderson, Vincent Falanga, Robert W. Simms, Joseph H. Korn, and Peter A. Merkel

Osteoarthritis

610 Knee Pain, Knee Osteoarthritis, and the Risk of Fracture

Nigel K. Arden, Sarah Crozier, Helen Smith, Frazer Anderson, Christopher Edwards, Helen Raphael, and Cyrus Cooper

Arthritis and Exercise

616 Perceived Exercise Barriers, Enablers, and Benefits Among Exercising and Nonexercising Adults With Arthritis: Results From a Qualitative Study

Sara Wilcox, Cheryl Der Ananian, Jill Abbott, JoEllen Vrazel, Cornelia Ramsey, Patricia A. Sharpe, and Teresa Brady

Systemic Lupus Erythematosus

Depression, Fatigue, and Pain in Systemic Lupus Erythematosus (SLE): Relationship to the American College of Rheumatology SLE Neuropsychological Battery

Elizabeth Kozora, Misoo C. Ellison, and Sterling West

REVIEW ARTICLES

636 Clinical Burden of Radiographic Hand Osteoarthritis: A Systematic Appraisal S. Dahaghin, S. M. A. Bierma-Zeinstra, J. M. W. Hazes, and B. W. Koes

648 Health Economic Evaluation: A Primer for the Practicing Rheumatologist Michael C. Y. Tan, Dean A. Regier, John M. Esdaile, Larry D. Lynd, Aslam H. Anis, and Carlo A. Marra

CONTRIBUTIONS FROM THE FIELD

657 Association of Anti-Cyclic Citrullinated Peptide and Anti-Sa/Citrullinated Vimentin Autoantibodies in Rheumatoid Arthritis

Margarita Rodríguez-Mahou, Francisco Javier López-Longo, Silvia Sánchez-Ramón, Ana Estecha, Aurea García-Segovia, Juan José Rodríguez-Molina, Luis Carreño, and Eduardo Fernández-Cruz

662 Do Training Diaries Affect and Reflect Adherence to Home Programs?

G. Lorimer Moseley

665 Conundrums in Nosology: Synovitis, Acne, Pustulosis, Hyperostosis, and Osteitis Syndrome and Spondylarthritis

G. Rohekar and R. D. Inman

670 Interpersonal Processes and Vasculitis Management

Megan A. Lewis, Carolyn T. Kalinowski, Katherine R. Sterba, Tracy M. Barrett, and Robert F. DeVellis

676 Patients and Professionals as Research Partners: Challenges, Practicalities, and Benefits

Sarah Hewlett, Maarten de Wit, Pam Richards, Enid Quest, Rod Hughes, Turid Heiberg, and John Kirwan

LETTERS

681 Anti-Cyclic Citrullinated Peptide Antibody Determination in the Synovial Fluid of Patients With Rheumatoid Arthritis: Comment on the Article by Caspi et al

Antonio Spadaro, Valeria Riccieri, Rossana Scrivo, Cristiano Alessandri, and Guido Valesini

682 Reply

Dan Caspi and Ori Elkayam

682 Submissions Invited for Themed Issue of Arthritis Care & Research: Cost and Social and Psychological Impact of Rheumatic Diseases

Volume 55, No. 5

October 15, 2006

EDITORIALS

- 683 Cyclooxygenase 2 Controversy: Thoughts on the Process of Discovery,
 Development, and Assessment of Benefit and Risk of Therapies for Chronic
 Immunoinflammatory Diseases of Uncertain Autoimmune Etiology
 Daniel E. Furst, Dinesh Khanna, and Harold E. Paulus
- 687 Examining the Consequences of Rehabilitation Interventions on Disease Progression and Functional Decline: Is Function Really the Only Thing That Matters?

G. Kelley Fitzgerald

► See articles, pages 690 and 779

ORIGINAL ARTICLES

Exercise

690 Effects of Strength Training on the Incidence and Progression of Knee Osteoarthritis

Alan E. Mikesky, Steven A. Mazzuca, Kenneth D. Brandt, Susan M. Perkins, Teresa Damush, and Kathleen A. Lane

- ► See editorial, page 687
- 700 Effect of Preoperative Exercise on Measures of Functional Status in Men and Women Undergoing Total Hip and Knee Arthroplasty

Daniel S. Rooks, Jie Huang, Benjamin E. Bierbaum, Sarah A. Bolus, James Rubano, Christine E. Connolly, Sandra Alpert, Maura D. Iversen, and Jeffrey N. Katz

Pediatric Rheumatology

709 Musculoskeletal Screening Examination (pGALS) for School-Age Children Based on the Adult GALS Screen

H. E. Foster, L. J. Kay, M. Friswell, D. Coady, and A. Myers

717 Use of the Sharp and Larsen Scoring Methods in the Assessment of Radiographic Progression in Juvenile Idiopathic Arthritis

Federica Rossi, Fiorella Di Dia, Olivia Galipò, Angela Pistorio, Maura Valle, Silvia Magni-Manzoni, Nicolino Ruperto, Paolo Tomà, Alberto Martini, and Angelo Ravelli

Osteoporosis

724 Successes and Failures in Improving Osteoporosis Care After Fragility Fracture: Results of a Multiple-Site Clinical Improvement Project

J. Timothy Harrington and Chad L. Deal

729 Patient Treatment Preferences for Osteoporosis

Liana Fraenkel, Barbara Gulanski, and Dick Wittink

Rheumatoid Arthritis

736 Disability, Social Support, and Distress in Rheumatoid Arthritis: Results from a Thirteen-Year Prospective Study

Mathilde M. H. Strating, Theo P. B. M. Suurmeijer, and Wijbrandt H. van Schuur

745 Comment on the Use of Self-Reporting Instruments to Assess Patients With Rheumatoid Arthritis: The Longitudinal Association Between the DAS28 and the VAS General Health

W. Kievit, P. M. J. Welsing, E. M. M. Adang, A. M. Eijsbouts, P. F. M. Krabbe, and P. L. C. M. van Riel

751 Assessing Utility Values in Rheumatoid Arthritis: A Comparison Between Time Trade-Off and the EuroQol

Rafael Ariza-Ariza, Blanca Hernández-Cruz, Loreto Carmona, Maria Dolores Ruiz-Montesinos, Javier Ballina, Federico Navarro-Sarabia, and the Costs and Quality of Life in Rheumatoid Arthritis Study Group

Epidemiology

757 Impact of Multiple Joint Problems on Daily Living Tasks in People in the Community Over Age Fifty-Five

Anne-Maree Keenan, Alan Tennant, Jon Fear, Paul Emery, and Philip G. Conaghan

765 Epidemiologic Surveillance of Upper-Extremity Musculoskeletal Disorders in the Working Population

Yves Roquelaure, Catherine Ha, Annette Leclerc, Annie Touranchet, Marine Sauteron, Maria Melchior, Ellen Imbernon, and Marcel Goldberg

Osteoarthritis

779 Course of Functional Status and Pain in Osteoarthritis of the Hip or Knee: A Systematic Review of the Literature

Gabriella M. van Dijk, Joost Dekker, Cindy Veenhof, and Cornelia H. M. van den Ende, for the CARPA Study Group

► See editorial, page 687

Gout

786 Using Serum Urate Levels to Determine the Period Free of Gouty Symptoms After Withdrawal of Long-Term Urate-Lowering Therapy: A Prospective Study

Fernando Perez-Ruiz, Joana Atxotegi, Iñaki Hernando, Marcelo Calabozo, and Joan M. Nolla

Myositis

791 Myositis-Specific and Myositis-Associated Antibodies in a Series of Eighty-Eight Mediterranean Patients With Idiopathic Inflammatory Myopathy

Albert Selva-O'Callaghan, Moisés Labrador-Horrillo, Roser Solans-Laque, Carmen Pilar Simeon-Aznar, Xavier Martínez-Gómez, and Miquel Vilardell-Tarrés

Systemic Lupus Erythematosus

799 Systemic Lupus Erythematosus in a Multiethnic US Cohort, XXXVII: Association of Lymphopenia With Clinical Manifestations, Serologic Abnormalities, Disease Activity, and Damage Accrual

Luis M. Vilá, Graciela S. Alarcón, Gerald McGwin, Jr, Holly M. Bastian, Barri J. Fessler, and John D. Reveille, for the LUMINA Study Group

REVIEW ARTICLE

807 Magnetic Resonance Spectroscopy in the Evaluation of Central Nervous System Manifestations of Systemic Lupus Erythematosus

Simone Appenzeller, Lilian T. L. Costallat, Li Min Li, and Fernando Cendes

CONTRIBUTION FROM THE FIELD

812 Switching From Infliximab to Once-Weekly Administration of 50 mg Etanercept in Resistant or Intolerant Patients With Ankylosing Spondylitis: Results of a Fifty-Four-Week Study

Fabrizio Cantini, Laura Niccoli, Maurizio Benucci, Daniela Chindamo, Carlotta Nannini, Ignazio Olivieri, Angela Padula, and Carlo Salvarani

CASE REPORTS

817 Development of Sarcoidosis During Etanercept Therapy

Marcos A. González-López, Ricardo Blanco, M. Carmen González-Vela, Héctor Fernández-Llaca, and Vicente Rodríguez-Valverde

821 Looking Beyond the Ordinary: Genital Lupus

Meenakshi Jolly and Purvi Patel

TRAINEE ROUNDS

823 Epstein-Barr Virus-Associated B Cell Lymphoproliferative Disease in a Child With Neonatal-Onset Multisystem Inflammatory Disease

Renee Modica, Helen Emery, Wilbur Lam, Michelle Hermiston, James Grenert, Michael Wirt, and Emily von Scheven

826 Case Report and Review of Cardiac Tamponade in Mixed Connective Tissue

Manisha S. Kumar, Michael Smith, and Ken D. Pischel

LETTERS

831 Additional Case of Minocycline-Induced Cutaneous Polyarteritis Nodosa: Comment on the Article by Culver et al

Sébastien Abad, Marianne Kambouchner, Mohamed Nejjari, and Robin Dhote

832 Reply

Brent Culver and Ken D. Pischel

832 Submissions Invited for Themed Issue of Arthritis Care & Research: Cost and Social and Psychological Impact of Rheumatic Diseases

Volume 55, No. 6

December 15, 2006

EDITORIAL

833 Status Report for Pediatric Rheumatology: What Needs to Be Done?

Murray Passo

► See article, page 836

ORIGINAL ARTICLES

Pediatric Rheumatology

836 Availability of Pediatric Rheumatology Training in United States Pediatric Residencies

Michelle L. Mayer, Laura Brogan, and Christy I. Sandborg

- ► See editorial, page 833
- 843 Correlation Between Juvenile Idiopathic Arthritis Activity and Damage Measures in Early, Advanced, and Longstanding Disease

Elena Palmisani, Nicoletta Solari, Silvia Magni-Manzoni, Angela Pistorio, Elena Labò, Serena Panigada, Alberto Martini, and Angelo Ravelli

850 Antiphospholipid Syndrome and Recurrent Thrombosis in Children

Y. Berkun, S. Padeh, J. Barash, Y. Uziel, L. Harel, M. Mukamel, S. Revel-Vilk, and G. Kenet

Rheumatoid Arthritis

856 Development and Validation of the Revised Cedars-Sinai Health-Related Quality of Life for Rheumatoid Arthritis Instrument

C. F. Chiou, C. D. Sherbourne, I. Cornelio, D. P. Lubeck, H. E. Paulus, M. Dylan, C. H. Chang, and M. H. Weisman

864 Long-Term Impact of Early Treatment on Radiographic Progression in Rheumatoid Arthritis: A Meta-Analysis

Axel Finckh, Matthew H. Liang, Carmen Mugica van Herckenrode, and Paola de Pablo

873 Osteoporosis Management in Patients With Rheumatoid Arthritis: Evidence for Improvement

Daniel H. Solomon, Jeffrey N. Katz, Danielle Cabral, Amanda R. Patrick,

Jack F. Bukowski, and Jonathan S. Coblyn

Patient Preferences

878 Patients' Preferences for Decision Making and the Feeling of Being Understood in the Medical Encounter Among Patients With Rheumatoid Arthritis

Hirono Ishikawa, Hideki Hashimoto, and Eiji Yano

Quality of Care

884 Application of Explicit Process of Care Measurement to Rheumatoid Arthritis: Moving from Evidence to Practice

K. L. Kahn, C. H. MacLean, H. Liu, L. Z. Rubenstein, A. L. Wong, J. O. Harker, W. P. Chen, D. M. Fitzpatrick, K. J. Bulpitt, S. B. Traina, B. S. Mittman, B. H. Hahn, and H. E. Paulus

Systemic Lupus Erythematosus

892 Prevalence of Conventional and Lupus-Specific Risk Factors for Cardiovascular Disease in Patients With Systemic Lupus Erythematosus: A Case-Control Study

Rupa Bessant, Rachel Duncan, Gareth Ambler, Jo Swanton, David A. Isenberg, Caroline Gordon, and Anisur Rahman

900 Association of Antinucleosome Antibodies With Disease Flare in Serologically Active Clinically Quiescent Patients With Systemic Lupus Erythematosus

K. P. Ng, J. J. Manson, A. Rahman, and D. A. Isenberg

Osteoarthritis

905 "What Do You Expect? You're Just Getting Older": A Comparison of Perceived Osteoarthritis-Related and Aging-Related Health Experiences in Middle- and Older-Age Adults

Monique A. M. Gignac, Aileen M. Davis, Gillian Hawker, James G. Wright, Nizar Mahomed, Paul R. Fortin, and Elizabeth M. Badley

913 Impact of the Diagnostic Label of Osteoarthritis on Perceptions of Disability and Willingness to Help a Parent in African Americans and Whites

Chivon A. Mingo, Jessica M. McIlvane, and William E. Haley

Rehabilitation and Physical Activity

920 Impact of Osteoarthritis on Rehabilitation for Persons With Hip Fracture

Tracy U. Nguyen-Oghalai, Kenneth J. Ottenbacher, Carl V. Granger, Sarah Toombs Smith, and James S. Goodwin

925 Effectiveness of Behavioral Graded Activity in Patients With Osteoarthritis of the Hip and/or Knee: A Randomized Clinical Trial

Cindy Veenhof, Albère J. A. Köke, Joost Dekker, Rob A. Oostendorp, Johannes W. J. Bijlsma, Maurits W. van Tulder, and Cornelia H. M. van den Ende

935 Using Internet Technology to Deliver a Home-Based Physical Activity
Intervention for Patients With Rheumatoid Arthritis: A Randomized Controlled
Trial

M. H. van den Berg, H. K. Ronday, A. J. Peeters, S. le Cessie, F. J. van der Giesen, F. C. Breedveld, and T. P. M. Vliet Vlieland

Muscle Strength and Functioning

946 Muscle Strength, Functional Performance, and Self-Reported Outcomes Four Years After Arthroscopic Partial Meniscectomy in Middle-Aged Patients

Ylva B. Ericsson, Ewa M. Roos, and Leif Dahlberg

953 Joint Laxity and the Relationship Between Muscle Strength and Functional Ability in Patients With Osteoarthritis of the Knee

M. van der Esch, M. Steultjens, D. L. Knol, H. Dinant, and J. Dekker

Ankylosing Spondylitis

960 Stability of the Patient Acceptable Symptomatic State Over Time in Outcome Criteria in Ankylosing Spondylitis

Florence Tubach, Thao Pham, Johan F. Skomsvoll, Knut Mikkelsen, Olav Bjørneboe, Philippe Ravaud, Maxime Dougados, and Tore K. Kvien

Therapeutics

964 Comparison of Efficacy of Arthroscopic Lavage Plus Administration of Corticosteroids, Arthroscopic Lavage Plus Administration of Placebo, and Joint Aspiration Plus Administration of Corticosteroids in Arthritis of the Knee: A Randomized Controlled Trial

M. van Oosterhout, J. K. Sont, I. M. Bajema, F. C. Breedveld, and J. M. van Laar

CONTRIBUTION FROM THE FIELD

971 Osteoporosis in the Home Health Care Setting: A Window of Opportunity? Jeffrey R. Curtis, Young Kim, Tara Bryant, Jeroan Allison, Dana Scott, and Kenneth G. Saag

CASE REPORTS

- 976 Septic Arthritis Caused by Abiotrophia defectiva
 Connie E. Taylor and Meika A. Fang
- 978 Pulmonary Sarcoidosis Developing During Infliximab Therapy
 Finbar D. O'Shea, Theodore K. Marras, and Robert D. Inman
- 981 Erratum
- 982 Evolution of Dermatomyositis During Therapy With a Tumor Necrosis Factor α Inhibitor

Harald A. Hall and Bernard Zimmermann

985 Giant Cell Arteritis: Involvement of Intracranial Arteries
Carlo Salvarani, Caterina Giannini, Dylan V. Miller, and Gene Hunder

LETTERS

990 Evaluation of Renal Improvement in Juvenile Systemic Lupus Erythematosus: Comment on the Articles by Ruperto et al

Stephen D. Marks and Kjell Tullus

- 991 Reply
 Nicolino Ruperto, Angelo Ravelli, and Alberto Martini, for the PRINTO Group
- 992 Revising the Classification Criteria for Systemic Sclerosis O. Nadashkevich, P. Davis, and M. J. Fritzler
- 993 Submissions Invited for Themed Issue of Arthritis Care & Research: Cost and Social and Psychological Impact of Rheumatic Diseases

- 11A ANNOUNCEMENTS
- 994 REVIEWERS 2006
- 999 VOLUME 55 TABLE OF CONTENTS
- 1017 AUTHOR INDEX TO VOLUME 55 (2006)
- 1020 SUBJECT INDEX TO VOLUME 55 (2006)

AUTHOR INDEX

Arthritis Care & Research, Volume 55, Numbers 1-6, 2006

A

Abad S, 831 Abbott J. 616 Abraído-Lanza AF, 224, 442 Abramson SB, 543 Ackerman IN, 583 Adang EMM, 745 Aggarwal A, 355 Ahn CW, 466 Alarcón GS, 799 Alessandri C. 681 Alessio M, 355 Alexanderson H, 114 Allaire S, 294 Allison J. 420, 971 Alpert S, 700 Amabile N, 551 Ambler G, 892 Anderson F, 610 Anderson II, 603 Andersson-Gäre B, 355 Anis AH, 9, 648 Anouk M, 53 Apaz M, 355 Appenzeller S, 807 April KT, 558 Arden NK, 610 Ariza-Ariza R, 751 Armbrister AN, 442 Arnold E, 341 Arthritis Care, 189, 199 Assis MR, 57 Atxotegi J, 786 Avcin T, 355 Avorn J, 35, 513

Badley EM, 233, 905 Bae S-C, 355 Bair YA, 353 Bajema IM, 964 Baker N, 294 Bala M, 569 Ballina J, 751 Bandeen-Roche K, 256 Bandeira M, 177 Bar-Or O, 364 Barash J, 850 Barbosa CMP, 373 Baron G, 526 Barrett TM, 670 Barros Alves AM, 57 Bartlett SJ, 333 Bastian HM, 799 Basu D. 466 Bathon JM, 256, 325, 333 Bendahan D. 551 Bennell KL, 583 Benucci M, 812 Bergé E, 451 Berkun Y, 850 Bernatsky S, 531 Berrios-Rivera JP, 385 Bessant R. 892 Bhalla AK, 564 Bierbaum BE, 700 Bierma-Zeinstra SMA, 636 Bijlsma JWJ, 420, 480, 925

Bingham CO III, 325, 543 Birnbaum B. 501 Bjørneboe O, 960 Blanco R. 817 Bleiberg J, 434 Blizzard L, 264 Blockmans D, 131 Bobbaers H, 131 Boin F, 167 Bolus SA, 700 Bombardier C, 42, 402 Brady T, 616 Brandt KD, 690 Braun J, 569 Breedveld FC, 157, 935, 964 **British Society of Paediatric** and Adolescent Rheumatology, 189, 199 Britto MT, 378 Brogan L, 836 Broman L. 114 Brunner HI, 184, 378 Bruyn G, 341 Bryant T, 971 Buhl C, 451 Bukowski JF, 873 Bulpitt KJ, 884 Burgos-Vargas R, 355 Burmester G, 569 Busquets-Pérez N, 507 Buzio C, 126

Cabral D, 35, 513, 873 Calabozo M. 786 Cantini F. 812 Cao T, 493 Carmona L, 1, 751 CARPA Study Group, 779 Carreño L. 657 Caspi D, 53, 682 Castellsague J, 537 Caudmont C. 451 Cendes F, 807 Chabot I, 27 Chadha T, 163 Champey J, 451 Chang CH, 856 Chang JT, 241 Chang RW, 248 Chen WP, 884 Children's Chronic Arthritis Association, 189, 199 Chindamo D, 812 Chiou C-F, 339, 856 Choi HK, 19 Chung C, 575 Cicuttini F, 264 Cid MC, 160 Classification and Response Criteria Subcommittee of the American College of **Rheumatology Committee** on Quality Measures, 348 Coady D, 709 Coblyn JS, 873 Cohen S. 15 Collado A, 160

Conaghan PG, 757 Conner-Spady B, 575 Connolly CE, 700 Conte PM, 81 Cooley H, 264 Cooper C, 610 Corcoran MS, 378 Cornelio I, 856 Corona F, 355 CORRONA Investigators, 543 Corruble E, 451 Cortis E, 355 Costallat LTL, 807 Costigan PA, 94 Costs and Quality of Life in Rheumatoid Arthritis Study Group, 751 Covinsky K, 175 Coyte PC, 42, 402 Cozzone PJ, 551 Croft P, 411 Crossley KM, 306 Crozier S, 610 Culver B, 832 Curtis JR, 420, 971

Dagfinrud H, 394 Dahaghin S, 636 Dahlberg L, 946 Daikh DI, 322 Damush T, 690 Dasgupta B, 518 Davis AM, 42, 314, 402, 905 Davis P, 992 de Ceuninck L, 131 de Pablo P. 864 de Wit M, 676 Deal CL, 724 Dekker J, 480, 779, 925, 953 Der Ananian C, 616 DeVellis RF, 670 Devins GM, 172 DeVlam K, 569 Dhote R, 831 Di Dia F, 717 Diamond B, 434 Dieleman JP, 537 Dieppe P, 279, 515 Dinant H, 953 Ding C, 264 Dolezalova P, 355 Doré CJ, 473 Doria A, 427 Dougados M, 526, 960 Dreyfuss J. 74 Duarte C, 355 Duffy CM, 199, 558 Duffy MC, 123 Duncan R, 892 Dunlop DD, 248 Dylan M, 856

Edwards C. 610 Edwards RR, 325 Eijsbouts AM, 745 Elkayam O, 53, 682 Ellison MC, 628 Emery H, 823 Emery P, 757 Ericsson YB, 946 Esdaile JM, 9, 648 Espígol-Frigolé G, 160 Estecha A, 657 Evangelisto AM, 342

F

Falanga V, 603 Falissard B, 526 Fang MA, 976 Fear J. 757 Feldman BM, 364 Feldman D, 57 Feldman DE, 558 Fernández-Cruz E, 657 Fernández-Llaca H, 817 Fessler BI, 799 Figarella-Branger D, 551 Finckh A, 864 Finset A, 394 Fitzgerald GK, 687 Fitzpatrick DM, 884 Fontaine K, 333 Fortin PR, 905 Foster HE, 355, 709 Fraenkel L, 300, 729 Freeman A, 420 Fried LP, 256 Friswell M, 709 Fritzler MI. 992 Furst DE, 683

G Galipò O, 717 Ganz DA, 241 Garcia Popa-Lisseanu MG, 385 García-Martínez A, 160 Garcia-Munitis P, 177 Garcia-Porrua C, 150 García-Segovia A, 657 Ge Z, 493 Gelbard RB, 603 Gelber AC, 333 Genant HK, 343 Genovese MC, 287 George V, 420 Gerloni V, 355 Ghirardello A. 427 Ghisi M, 427 Giannini C, 985 Giannini EH, 355 Gignac MAM, 233, 272, 314, 905 Giles JT, 333 Gillis J. 322 Gliddon AE, 473 Golan I, 53 Goldberg M, 765 Gonzalez-Gay MA, 150 Gonzalez-Juanatey C, 150 González-López MA, 817 González-Vela MC, 817 Goodwin JS, 920 Gordon C, 892

Gottenberg J-E, 451 Graham TB, 378 Granger CV, 920 Grassi W, 341 Grau JM, 160 Graves SE, 583 Greco P, 126 Greenberg JD, 543 Grenert J, 823 Guan M, 241 Guis S, 551 Gulanski B, 729 Guller U, 591 Gusi N, 66

H

Ha C, 765 Hafezi-Rachti S, 146 Hagan RA, 123 Hagelberg S, 355 Hahn BH, 884 Häkkinen A, 66 Häkkinen K. 66 Haley WE, 913 Hall HA, 982 Han C. 569 Han J, 569 Hanssen AD, 123 Hardy P, 451 Harel L, 850 Harker IO, 884 Harrington JT, 724 Hashimoto H, 878 Hawker G, 272, 905 Hawkins M, 458 Haythornthwaite JA, 325 Hazes JMW, 636 Heiberg T, 676 Heng BC, 493 Herlin T, 355 Hermiston M. 823 Hernandez JE, 163 Hernández-Cruz B, 751 Hernández-Rodríguez J, 160 Hernando I. 786 Hewlett S, 676 Higgins LD, 591 Highton J, 154 Hilário MOE, 373 Hinkle K, 543 Hinman RS, 306 Holmboe ES, 300 Horneff G, 355 Hu Y, 493 Huang J, 700 Hübscher O, 340 Hudson M. 531 Hughes R, 676 Huizinga TWJ, 157 Hunder G. 985 Hung NA, 154 Hunsche E. 27 Hutchings A, 518

I

laccarino L, 427 Illei G, 434 Imbernon E, 765 Inman RD, 665, 978 Isenberg DA, 892, 900 Ishikawa H, 878 Iversen MD, 700

Ĭ

Jackson C, 154 Jacobs G, 434 Jacobs P, 337 Jain NB, 591 Janssen NM, 385 Jauregui E, 575 Jick SS, 19 Jolly M, 821 Jones G, 264 Josefson A, 114 Juarez L, 102

K

Kahn KL, 884 Kalinowski CT, 670 Kallen MA, 385 Kamberg CJ, 241 Kambouchner M, 831 Kanakoudi-Tsakalidou F, 355 Kane D. 341 Karadimitrakis SP, 598 Katz JN, 591, 700, 873 Katz PP, 3, 17., 717, 345 Kaufman I, 53 Kay Ll. 709 Keenan A-M, 757 Kenet G, 850 Khanna D, 683 Khullar M, 564 Kievit W. 745 Kim Y, 971 Kimura Y, 81 Kirwan J, 676 Kishimoto M. 543 Kissin EY, 603 Kjeken I, 394 Klein-Gitelman MS, 184 Knockaert D. 131 Knol DL, 953 Koes BW, 636 Köke AJA, 925 Korn IH. 603 Kotagal UR, 378 Kovac SH, 420 Kozak-Ribbens G, 551 Kozora E, 628 Krabbe PFM, 745 Kramer SL, 378 Kravitz RL, 353 Kremer J, 543 Krizova A, 138 Kumar MS, 826 Kvien TK, 394, 960 Kwoh CK, 513

I

Labò E, 843
Labrador-Horrillo M, 791
Lady Hoare Trust for
Physically Disabled
Children, 189, 199
Lam W, 823
Lane KA, 690
Lapteva L, 434
LaValley M, 294
le Cessie S, 935
Le Fur Y, 551
LeBlanc K, 521
Leclerc A, 765
Lee EH, 493
Leite de Barros Neto T, 57

Len CA, 373 Lepore L, 355 Levartovsky D, 53 Lewallen DG, 123 Lewis MA, 670 Li LC, 42, 402 Li LM. 807 Liang MH, 864 Lieberman ES, 19 Lindsley HB, 343 Lineker SC, 42, 402 Ling SM, 256 Link BG, 442 Litinsky I, 53 Liu H. 884 Llorca J. 150 Lockshin MD, 345 Logeart I, 526 López-Longo FJ, 657 Loyd M, 337 Lubeck DP, 856 LUMINA Study Group, 799 Lundberg IE, 114 Lynd LD, 9, 648

M

MacLean CH, 241, 884

Maddison PJ, 473 Maetzel A, 402 Magni-Manzoni S, 177, 717, 843 Mahomed NN, 314, 905 Maksymowych WP, 575 Malley JD, 74 Mallon C, 575 Maly MR, 94 Mann C. 279 Manson JJ, 900 Marcus DM, 385 Mariette X. 451 Marks SD, 990 Marra CA, 9, 648 Marras TK, 978 Martin J, 150 Martínez-Gómez X, 791 Martini A. 177, 355, 717, 843, 991 Martorana D, 126 Mattei JP, 551 Matteson EL, 123, 518 May RL, 306 Mayer ML, 836 Mazzuca SA, 690 McDonagh JE, 189, 199 McGwin G Jr. 799 McIlvane JM, 913 Melchior M. 765 Melson PG, 378 Merkel PA, 603 Meyer T, 451 Michaud K. 294 Mihaylova D. 355 Mikesky AE, 690 Mikkelsen K, 960 Miller DV, 985 Mingo CA, 913 Mittman BS, 884 Modica R, 823 Mogun H, 35, 513 Montala N, 507 Moreland LW, 287 Moroni G, 126

Mortelmans L, 131

Moseley GL, 662 Mosis G, 537 Moutsopoulos HM, 598 Mowinckel P, 394 Mukamel M, 850 Myers A, 709

N

Nadashkevich O, 992 Nanda S, 333 Nannini C, 812 Narváez J, 507 Natour J, 57 Navarro-Sarabia F, 751 Nejjari M, 831 Neri TM, 126 Ng KP, 900 Nguyen-Oghalai TU, 920 Niccoli L, 812 Nicholson M, 154 Nicoli F, 551 Nigrovic PA, 208 Niu F, 241 Niu I, 294 Nolla JM, 507, 786 Norambuena X, 355 Nowak M, 434

.

Ofman JJ, 339 Oliveira LM, 373 Oliveira S, 355 Olivieri I, 812 Olmsted ME, 86 Olney SJ, 94 Oostendorp RA, 925 Ortega-Alonso A, 66 Osborne RH, 458, 583 O'Shea FD, 978 Osmon DR, 123 Ottenbacher KJ, 920 Ouimet JM, 138 Ouyang H, 493

1

Padeh S, 850 Padula A. 812 Paediatric Rheumatology International Trials Organisation (PRINTO), 355, 991 Pajevic S, 74 Palmisani E, 843 Panigada S, 843 Paran D, 53 Pasic S. 355 Passo MH, 378, 833 Patel P, 821 Patel R, 123 Patrick AR, 873 Paulus HE, 683, 856, 884 Peat G, 411 Pediatric Rheumatology Collaborative Study Group (PRCSG), 355 Pedroso GC, 373 Peeters AJ, 935 Pellet J, 451 Pellissier JF, 551 Perez-Ruiz F, 786 Perini G, 427 Perkins SM, 690

Pessanha AP, 57 Pham T, 960 Phillips K, 340 Pietrobon R, 591 Pile K, 575 Pillinger MH, 501 Piper KE, 123 Pischel KD, 826, 832 Pisters MF, 480 Pistorio A, 177, 355, 717, 843 Plastiras SC, 598 Platt RW, 558 Pope JE, 138 Puccini PF, 373

Q

Quest E, 676 QUINS Trial Study Group, 473

R

Rahman A, 892, 900 Rahman MU, 19 Rahme E, 27 Ramsey C, 616 Raphael H, 610 Ravaud P. 526, 960 Ravelli A, 177, 355, 717, 843, 991 Reed G, 543 Regier DA, 648 Reich JW, 86 Reuben DB, 241 Reveille ID, 385, 466, 799 Revel-Vilk S, 850 Revenson TA, 224 Riccieri V, 681 Richards P, 676 Richardson MN, 385 Richardson R. 575 Rinaldi S, 427 Rodríguez-Mahou M, 657 Rodríguez-Molina JJ, 657 Rodríguez-Valverde V, 817 Roebuck-Spencer TM, 434 Roemer FW, 343 Rohekar G. 665 Ronconi L. 427 Ronday HK, 935 Rooks DS, 700 Roos EM, 946 Roquelaure Y, 765 Rossi F, 717 Rossum Mv, 355 Roth CP, 241 Rubano J. 700 Rubenstein LZ, 884 Rublee D, 337 Ruffing V. 333 Ruiz-Montesinos MD, 751 Ruperto N, 177, 355, 717, 991 Rupprecht HD, 146 Russell AS, 575

S

Saad CM, 355 Saag KG, 420, 971 Sale JEM, 272 Salvarani C, 126, 812, 985 San Miguel MT, 12 Sanavio E, 427 Sánchez-Ramón S, 657 Sandborg CI, 836 Sarzi-Puttini P. 427 Sato R, 287 Sauteron M, 765 Savi M, 126 Schanberg LE, 81 Schiller AM, 603 Schivo A, 177 Schoe A, 157 Sciubba JJ, 167 Scott D. 971 Scrivo R, 681 Selva-O'Callaghan A, 791 Sharpe PA, 616 Shaw KL, 189, 199 Shekelle PG, 241 Sherbourne CD, 856 Sherrard TM, 184 Sidhu GS, 501 Silva EK. 373 Silva LE, 57 Simeon-Aznar CP, 791 Simms RW, 603 Simon LS, 4 Simonsick EM, 256 Singh A, 287 Singh S, 564 Singh-Grewal D. 364 Skomsvoll JF, 960 Smith H, 610 Smith M. 826 Smith RL, 501 Smith ST, 920 Solans-Laque R, 791 Solari N. 843 Solomon DH, 35, 513, 873 Song J. 248 Sont IK. 964 Southwood TR, 189, 199 Spadaro A, 681 Spettell CM, 420 Spiegel BMR, 339 Sprangers MAG, 458 Srikanth V. 264 Starz TW, 513 Steckelberg JM, 123 Stenström CH, 114 Sterba KR, 670 Steultjens M, 953 Stijnen T, 537 Stone JH, 167 Strating MMH, 736 Street RL Jr, 385 Stricker BHC, 537 Sturkenboom MCJM, 537

Stürmer T, 35, 513

Suarez-Almazor ME, 385 Sugarman E, 81 Suissa S, 531 Suter LG, 300 Sutton D, 233 Suurmeijer TPBM, 736 Swanton J, 892

T

Tagoe CE, 501 Takada K, 434 Tan MCY, 648 Taylor CE, 976 Taylor J. 378 Tennant A, 757 Terreri MT, 373 Thiele RG, 342 Thomas E, 411 Tian I, 256 Todesco S, 427 Tollbäck A, 114 Tomà P, 717 Tomas-Carus P. 66 Toubouti Y, 27 Touranchet A, 765 Trail L. 355 Traina SB, 884 Tubach F, 526, 960 Tullus K, 990 Tyndall A, 521 Tzelepis GE, 598

L

Uhlig T, 394 Uziel Y, 850

Vaglio A, 126

V

Vaillant G, 35, 513 Valesini G, 681 Valim V, 57 Valle M, 717 Valverde J, 507 van den Berg MH, 935 van den Bosch F, 569 van den Ende CHM, 480, 779, 925 van der Esch M, 953 van der Giesen Fl. 935 van der Heijde D, 569 van der Laan-Baalbergen NE, 157 van der Lei J, 537 van Diik GM, 480, 779 van Herckenrode CM, 864 van Holsbeeck M, 343 van Laar JM, 157, 964 van Oosterhout M. 964 van Puvmbroeck, 86 van Riel PLCM, 745 van Schuur WH, 736 van Tulder MW, 925

Vanderschueren S, 131 Vargas E, 12 Veenhof C, 480, 779, 925 Venkataramanan V, 314 Verbrugge LM, 102 Verma S, 564 Vesely R, 355 Vilá LM, 799 Vilardell-Tarrés M, 791 Vlachoyiannopoulos PG, 598 Vliet Vlieland TPM, 935 Vogt MT, 513 Volpe B, 434 von Scheven E, 823 Vrazel J, 616

W

Walco GA, 81 Wang PS, 35, 513 Ward MM, 74 Warner NB, 385 Wechsler R, 373 Weickert T, 434 Weidner S, 146 Weinblatt ME, 340 Weisman MH, 856 Welsing PMJ, 745 Wenger NS, 241 West S, 628 Westfall AO, 420 White K, 442 White PH, 208 White RH, 353 Wigler I, 53 Wilcox S. 616 Williams FM, 466 Williamson P. 569 Wirt M. 823 Wittink D, 729 Wofsy D, 322 Wolfe F. 294 Wong AL, 884 Wright IG, 905 Wright V, 364

X

Xue QL, 256

Y

Yang Z, 493 Yano E, 878 Yarboro C, 434 Yelin EH, 3, 171, 345

Z

Zampieri S, 427 Zanetti A, 126 Zappala L, 575 Zhai G, 264 Ziakas PD, 598 Zimmermann B, 982

SUBJECT INDEX

Arthritis Care & Research, Volume 55, Numbers 1-6, 2006

A

Abiotrophia defectiva, septic arthritis caused by, 976

Acne, SAPHO, and SpA, 665

Activity limitation. See also Disability

aging, arthritis, and disability, 175

Acute lupus pneumonitis, fulminating hydralazine-induced lupus pneumonitis, 501

Acute myocardial infarction, DMARDs and risk of, 531

Adalimumab, pulmonary fibrosis in RA patient treated with, 157 Adherence. See Treatment adherence

Adjustment processes

illness intrusion and psychological adjustment to, social identity framework in, 224

interpersonal processes and vasculitis management, 670

Adolescents

JIA, health-related quality of life in adolescents with, 199 JIA, parents as proxies of adolescents with, 189

tool for early referral for chronic arthropathy, 373

Adverse effects

adalimumab, pulmonary fibrosis in RA patient, 157 coxibs and prevalence of cardiovascular contraindications, 537

DMARDs and risk of acute myocardial infarction, 531 glucocorticoid long-term use and, 420

statin myotoxicity, 551

Aerobic exercise, $\vec{F}M$, clinical effectiveness of deep water running, 57

Aging. See also Older adults

arthritis and disability and, 175

comparison of perceived OA-related and aging-related health experiences, 905

American College of Rheumatology (ACR)

ACR-SLE neuropsychological battery, 628

classification and response criteria for rheumatic diseases, 348, 992

prospective validation of definition of improvement in pediatric SLE, 355, 990

Animal studies, RANK ligand in normal and pathologic bone remodeling, potential for novel inhibitory molecules in, 15 Ankylosing spondylitis (AS)

Edmonton Ankylosing Spondylitis Metrology Index: development and validation of, 575

infliximab improves productivity and reduces workday loss, 569

pulmonary sarcoidosis during infliximab therapy, 978

rheumatology care, involvement in medical decisions, received information, satisfaction with care, and unmet health care needs in 394

stability of the Patient Acceptable Symptomatic State over time in outcome criteria, 960

switching from infliximab to once-weekly etanercept in resistant or intolerant patients, 812

Anti-cyclic citrullinated protein antibody (anti-CCP)

anti-CCP and anti-Sa/citrullinated vimentin autoantibodies in RA, 657

synovial fluid levels in RA, PsA, and OA, 53, 681

Antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis

interpersonal processes and, 670

thromboembolic events as complication of, 146

Antinucleosome antibodies, disease flare in SLE and, 900

Antiphospholipid syndrome (APS), recurrent thrombosis and in children, 850

Anti-Sa antibodies, anti-CCP and anti-Sa/citrullinated vimentin autoantibodies in RA, 657

Anti-tumor necrosis factor (anti-TNF)

AS, infliximab improves productivity and reduces workday loss, 569 Anti-tumor necrosis factor (anti-TNF) (cont'd)

AS, switching from inflixing to once-weekly etanercept in resistant or intolerant patients, 812

etancercept-related DM, 982

infliximab-related lupus and associated valvulitis, 163

PsA, etanercept-induced granulomas, 340

pulmonary sarcoidosis during infliximab therapy, 978

RA, effect of etanercept on fatigue, 287

RA, infliximab for progression of subclinical atherosclerosis in, 150

RA, pulmonary fibrosis in RA patient treated with adalimumab, 157

sarcoidosis during etanercept therapy, 817

Anxiety, in SS and sicca symptoms without autoimmune features, 451

Aquatic exercise

FM, clinical effectiveness of deep water running, 57

FM, pool exercise in waist-high warm water and health-related quality of life and lower extremity strength, 66

Arthritis

aging, disability and, 175

arthritis-work spillover among employed adults, 233

catastrophizing and pain in, 325

exercise barriers, enablers, and benefits among exercising and nonexercising adults with, 616

health status, activity limitations, and disability in work and housework in Latino and non-Latino arthritis patients, 442

knee arthritis, comparison of arthroscopic lavage plus corticosteroid administration, arthroscopic lavage plus placebo, and joint aspiration plus corticosteroid administration in, 964

population impact on disability in older adults, 248 profile of disability, 102

septic arthritis caused by Abiotrophia defectiva, 976

Arthritis Care & Research (AC&R), journal policies on authorship and disclosures, 345

Arthroplasty. See Joint replacement

Arthroscopic lavage, knee arthritis, comparison of arthroscopic lavage plus corticosteroid administration, arthroscopic lavage plus placebo, and joint aspiration plus corticosteroid administration in, 964

Assessment

JIA, Sharp and Larsen scoring of radiographic progression in, 717

knee OA, staging joint pain and disability, 411

musculoskeletal screening examination (pGALS) for school-age children based on the adult GALS screen, 709

OA, psychometric evaluation of OA questionnaires, 480

SLE, behavioral correlates of the ACR-SLE battery, 628

SLE, computerized cognitive testing for, 434

SSc, durometry for assessment of skin disease in, 603 tool for early referral for chronic arthropathy, 373

Atherosclerosis

RA, anti-TNF α therapy for progression of subclinical atherosclerosis in, 150

SLE, risk factors for cardiovascular disease in patients with, 892 Autoimmune disease

chronic periaortitis and HLA-DRB1*03, 126

inhibition of T cell costimulation as emerging the rapeutic strategy, 322

stem cells and rheumatology, 521

Automated Neuropsychological Assessment Metrics (ANAM), computerized cognitive testing for SLE, 434

B

Back, prescription opioid use among older adults for arthritis and low back pain, 35, 513

Bath Ankylosing Spondylitis Metrology Index (BASMI), 575 Behavioral graded activity, effect on patients with OA of hip or knee, 925 Biologic response modifying agents, mandating coverage of biologic therapies for rheumatic diseases, 353

Bisphosphonates, patient treatment preferences for osteoporosis, 729

Body weight, OA in lower extremities, 256

Bone. See also Osteoporosis

OA, subchondral bone and, 493

RANK ligand in normal and pathologic remodeling, potential for novel inhibitory molecules in, 15 SAPHO and SpA, 665

Bone marrow lesions, correlates of knee pain in older adults, 264

C

Canada

drug approval process and access to prescription drugs in, 9 rofecoxib withdrawal, retrospective analysis of utilization patterns and cost implications among Canadian seniors and, 27 Cardiovascular events

cardiac tamponade in MCTD, 826

coxibs and prevalence of cardiovascular contraindications, 537 DMARDs and risk of acute myocardial infarction, 531

RA, anti-TNFα therapy for progression of subclinical atherosclerosis in, 150

SLE, risk factors for cardiovascular disease in patients with, 892 Caregivers, relationship satisfaction in FM and OA patients, 86

Carpal tunnel syndrome, epidemiologic surveillance of upperextremity musculoskeletal disorders in working population,

Cataracts, long-term glucocorticoid use and, 420

Catastrophizing, in arthritis, FM, and other rheumatic diseases,

Celecoxib, coxib withdrawal, retrospective analysis of utilization patterns and cost implications among Canadian seniors and,

Cerebrovascular events, GCA, involvement of intracranial arteries, 985

Child Adherence Report Questionnaire (CARQ), 558

Childbearing, RA, childbearing decisions and family size among women with, 217

Children. See also Juvenile

APS and recurrent thrombosis in, 850 DM, subcutaneous fat in juvenile DM, 564

EBV-associated B cell lymphoproliferative disease with NOMID,

JIA, level of agreement between children, parents, and physicians in rating pain intensity, 177

JIA, perceived treatment adherence by children with JIA and their parents, 558

musculoskeletal screening examination (pGALS) for school-age children based on the adult GALS screen, 709

pediatric rheumatology, status report, 833 polyarticular childhood arthritis, fitness training and exercise testing in, 364

SLE, cost of treatment of childhood-onset SLE, 184

SLE, PRINTO/ACR for response to therapy in juvenile SLE, 355,

tool for early referral for chronic arthropathy, 373

Chondral defect, correlates of knee pain in older adults, 264 Chronic disease

chronic periaortitis and HLA-DRB1*03, 126

interpersonal processes and chronic disease, 670

measurement of chronic disease self-management programs, 458

tool for early referral for chronic arthropathy, 373

Churg-Strauss syndrome, presenting with salivary gland enlargement and respiratory distress, 167

Citrullinated vimentin, anti-CCP and anti-Sa/citrullinated vimentin autoantibodies in RA, 657

Classification tree, short-term prediction of SLE mortality using random forests, 74

CNS vasculitis, GCA, involvement of intracranial arteries in, 985 Cognitive functioning, computerized cognitive testing for SLE, 434

Collagenous colitis, spondylarthropathy and, 507

Communication

patients' preferences for decision making and feeling of being understood in medical encounter in RA patients, 878 trust in physicians in RA and SLE patients, 385

Comorbidity, OA, impact on rehabilitation for hip fracture, 920 Compliance. See Treatment adherence

Computers

computerized cognitive testing for SLE, 434

Internet technology to deliver home-based physical activity in-tervention for RA patients, 935

Coping

catastrophizing and pain in arthritis, FM, and other rheumatic diseases, 325

SLE, coping skills and health-related quality of life, 427

JIA, correlation between activity and damage measures in early, advanced, and longstanding disease, 843

SLE, PRINTO/ACR, prospective validation of definition of improvement in juvenile SLE, 355, 990

Corticosteroids, knee arthritis, comparison of arthroscopic lavage plus corticosteroid administration, arthroscopic lavage plus placebo, and joint aspiration plus corticosteroid administration in, 964

Cost assessment

childhood-onset SLE, cost of treatment of, 184

health economic evaluation, primer for clinicians, 648 rofecoxib withdrawal: retrospective analysis of utilization patterns and cost implications among Canadian seniors, 27

Cost-effectiveness

health economic evaluation: primer for clinicians, 648 of NSAID drug strategies, 338

of primary therapist model in RA, 402 Cyclooxygenase (COX) inhibitors

cardiovascular contraindications, 537

coxib utilization prior to market withdrawals, 543 editorial, 683

risk of acute myocardial infarction, 531

rofecoxib withdrawal, retrospective analysis of utilization patterns and cost implications among Canadian seniors, 27

D

Decision making

AS, involvement in medical decisions, received information, satisfaction with care, and unmet health care needs, 394 osteoporosis, patient treatment preferences, 729

RA, childbearing decisions and family size, 217

RA. patients' preferences for decision making and feeling of being understood in medical encounter, 878

Deep water running, for FM, clinical effectiveness of, 57 Depression

SLE, behavioral correlates of the ACR-SLE battery, 628 SS and sicca symptoms without autoimmune features, 451 Dermatomyositis (DM)

during etanercept therapy, 982

Functional Index-2, validity and reliability of disease-specific measure of impairment, 114

subcutaneous fat in juvenile DM, 564

Diffuse infiltrative lymphocytosis syndrome, 466

Disability. See also Functional disability; Work disability aging, arthritis and, 175

arthritis-work spillover among employed adults, 233

Functional Index-2, PM and DM with, 114

health status, activity limitations, and disability in work and housework in Latino and non-Latino arthritis patients, 442 JRA, insurance status and disease outcome, 378

knee OA, joint laxity and relationship between muscle strength

and functional ability, 953 OA, impact of diagnostic label on perceptions of disability and willingness to help a parent, 913

OA, impact on rehabilitation for hip fracture, 920 population impact of arthritis on disability in older adults, 248

profile of arthritis disability, 102

Disability. See also Functional disability; Work disability (cont'd) RA, social support, distress and, 736

staging joint pain and, 411

Disease activity

JIA, correlation between activity and damage measures in early, advanced, and longstanding disease, 843

JRA, insurance status and disease outcome, 378

lymphopenia in SLE, association with clinical manifestations, serologic abnormalities, disease activity, and damage accrual, 799

PRINTO/ACR, prospective validation of definition of improvement in juvenile SLE, 355, 990

Disease Activity Score (DAS), RA, self-reporting instruments to assess RA, association between DAS28 and VAS general health in, 745

Disease damage

JIA, correlation between activity and damage measures in early, advanced, and longstending disease, 843

lymphopenia in SLE, association with clinical manifestations, serologic abnormalities, disease activity, and damage accrual, 799

Disease flare, SLE, antinucleosome antibodies association with, 900

Disease-modifying antirheumatic drugs (DMARDs)

explicit process of care measurement applied to RA, 884 long-term impact of early treatment on radiographic progression in RA, 864

risk of acute myocardial infarction with, 531

Disease progression

consequences of rehabilitation on disease progression and functional decline, 687

JIA, correlation between activity and damage measures in early, advanced, and longstanding disease, 843

RA, long-term impact of early treatment on radiographic progression of, 864

strength training and progression of knee OA, 690

DNA, human retrovirus-4 proviral DNA in OA and RA, 123 Doctor-patient relationship. See Patient-doctor relationship Drug evaluation

approval process in Canada, 9

approval process in European Union, 12

Food and Drug Administration evaluation and approval process in US, 4

introduction to, 3

Drug-induced lupus, infliximab-related lupus and associated valvulitis: case report and literature review of, 163

Drug utilization

antirheumatic drug use and risk of acute myocardial infarction, 531

channeling coxibs and prevalence of cardiovascular contraindications, 537

coxib utilization prior to market withdrawals, 543

coxib withdrawal, retrospective analysis of utilization patterns and cost implications among Canadian seniors, 27

prescription opioid use among older adults for arthritis and low back pain, 35, 513

Durometry, for assessment of skin disease in SSc, 603

E

Economic evaluation, primer for clinicians, 648 Edmonton Ankylosing Spondylitis Metrology Index, 575

Elderly. See Older adults Employment. See also Work disability

arthritis-work spillover among employed adults, 233

epidemiologic surveillance of upper-extremity musculoskeletal disorders in working population, 765

infliximab improves productivity and reduces workday loss in AS patients, 569

occupational hand use in persons with RA, 294

Epidemiology

epidemiologic surveillance of upper-extremity musculoskeletal disorders in working population, 765

total shoulder arthroplasty, trends in, 591

Epstein-Barr Virus (EBV), EBV-associated B cell lymphoproliferative disease with NOMID, 823

Erratum, 981

Etanercept

AS, switching from infliximab to once-weekly etanercept in resistant or intolerant patients, 812

DM development during therapy, 982

PsA, etanercept-induced granulomas, 340

RA, effect of etanercept on fatigue, 287

sarcoidosis development during therapy, 817 Ethnicity, health status, activity limitations, and disability in work and housework in Latino and non-Latino arthritis patients, 442

European Union, drug evaluation and approval process in, 12 EuroQol-5D, utility values and quality-adjusted life years, comparing Time Trade-Off and EuroQol, 751

Exercise

exercise barriers, enablers, and benefits among exercising and nonexercising adults, 616

FM, clinical effectiveness of deep water running, 57

FM, pool exercise in waist-high warm water, health-related quality of life, and lower extremity strength, 66

OA of hip or knee, behavioral graded activity for, 925

polyarticular childhood arthritis, fitness training and exercise testing in, 364

preoperative exercise and functional status for total hip and knee arthroplasty, 700

RA, using Internet technology to deliver a home-based physical activity intervention for RA patients with, 935

training diaries and treatment adherence, 662

F

Family. See also Relationships

impact of diagnostic label of OA on perceptions of disability and willingness to help a parent, 913

RA, childbearing decisions and family size among women with, 217

Fatigue

RA, effect of etanercept on, 287

SLE, behavioral correlates of the ACR-SLE battery, 628

Fibromyalgia (FM)

catastrophizing and pain in, 325

deep water running, clinical effectiveness of, 57

exercise in waist-high warm water, health-related quality of life, lower extremity strength and, 66

relationship satisfaction, illness uncertainty and partner caregiver burden and support, 86

Fitness. See also Exercise

polyarticular childhood arthritis, fitness training and exercise testing in, 364

Food and Drug Administration, drug evaluation and approval process, 4

Forced vital capacity, as predictor of pulmonary function decline in SSc, 598

Fractures

knee pain, knee OA, and risk of, 610 long-term glucocorticoid use and, 420

osteoporosis care after fragility fracture, 724

osteoporosis in the home health care setting and, 971

rehabilitation for hip fracture, impact of OA on rehabilitation, 920

Functional disability

among Latinos and non-Latinos with arthritis, 442

consequences of rehabilitation on disease progression and functional decline, 687

multiple joint problems and daily living tasks in older adults, 757

population impact of arthritis on disability in older adults, 248 profile of arthritis disability, 102

RA, social support, distress, and disability, 736

Functional Index-2, validity and reliability of disease-specific measure of impairment for PM and DM, 114 **Functional status**

Functional Index-2, PM and DM, 114

hip and knee OA, functional status and pain, literature review

knee OA, joint laxity and relationship between muscle strength and functional ability, 953

meniscectomy and, muscle strength, functional performance, and self-reported outcomes 4 years after partial meniscectomy, 946

preoperative exercise and functional status for total hip and knee arthroplasty, 700

profile of arthritis disability, 102

Gastroprotection

channeling coxibs and prevalence of cardiovascular contraindications, 537

coxib utilization prior to market withdrawals, 543 Genetics, chronic periaortitis and HLA-DRB1*03, 126

Genital lupus, 821

Giant cell arteritis (GCA)

8F-fluorodeoxyglucose positron emission tomography in, 131 involvement of intracranial arteries, 985 sustained spontaneous clinical remission in, 160

Glucocorticoid-induced osteoporosis, in patients with RA, 873 Glucocorticoids

adverse events with long-term use, 420 and tuberculosis, risk of, 1, 19

Gout, serum urate levels to determine the period free of symptoms after withdrawal of therapy, 786

Granulomas

PsA, etanercept-induced granulomas, 340 pulmonary sarcoidosis during infliximab therapy, 978 sarcoidosis development during etanercept therapy, 817

Hand

epidemiologic surveillance of upper-extremity musculoskeletal disorders in working population, 765

OA, clinical burden of radiographic hand OA, 636 RA, occupational hand use in persons with RA, 294

Health care costs. See Cost assessment; Cost-effectiveness Health Education Impact Questionnaire (HEI-Q), measurement of chronic disease self-management programs, 458

Health insurance, JRA, insurance status and disease outcome, 378 Health-related quality of life

FM, pool exercise in waist-high warm water and, 66

JIA, in adolescents, 199

JIA, parents as proxies of adolescents with, 189

JRA, insurance status and disease outcome, 378 SLE, coping skills and health-related quality of life, 427

Health status among Latinos and non-Latinos with arthritis, 442

comparison of perceived OA-related and aging-related health experiences, 905

in patients with limited cutaneous SSc, 473

Hematopoietic stem cell transplantation, update on adult stem cell therapy in autoimmune diseases, 521

Highly active retroviral treatment (HAART), diffuse infiltrative lymphocytosis syndrome, 466

Hip

AS, development and validation of Edmonton Ankylosing Spondylitis Metrology Index, 575

correlates of knee pain in older adults, 264

multiple joint problems and daily living tasks in older adults,

OA, literature review of functional status and pain, 779

OA, pain medication and adherence to treatment in older adults, 272

rehabilitation for hip fracture, impact of OA on, 920 Hip replacement

preoperative exercise and functional status for total hip and knee arthroplasty, 700

Hip replacement (cont'd)

quality of life in, World Health Organization Quality of Life Short Version Instrument, 583

Hispanics, health status, activity limitations, and disability in work and housework in Latino and non-Latino arthritis patients, 442

HLA system, chronic periaortitis and HLA-DRB1*03, 126

Home health care, osteoporosis care in, 971

Hospitals, prediction of SLE mortality, classification of outcomes using random forests for, 74

Human immunodeficiency virus infection, diffuse infiltrative lymphocytosis syndrome in, 466

Human retrovirus-4, proviral DNA in OA and RA, 123

Hydralazine, fulminating hydralazine-induced lupus pneumonitis, 501

Hydrotherapy

FM, clinical effectiveness of deep water running, 57

FM, pool exercise in waist-high warm water and health-related quality of life and lower extremity strength, 66

Hypertriglyceridemia, subcutaneous fat in juvenile DM, 564

Identity-relevant stress hypothesis, illness intrusion and psychological adjustment to, social identity framework in, 224

Idiopathic inflammatory myopathy, myositis-specific and myositis-associated antibodies in, 791

IgA rheumatoid factor, synovial fluid levels in RA, PsA, and OA, 53, 681

Illness intrusiveness

illness intrusion and psychological adjustment to, social identity framework in, 224

psychologically meaningful activity, quality of life in rheumatic diseases and, 172

relationship satisfaction in FM and OA, 86

Imaging

adult with JRA, 208

chronic periaortitis and HLA-DRB1*03, 126

Churg-Strauss syndrome presenting with salivary gland enlargement and respiratory distress, 167

collagenous colitis and spondylarthropathy, 507 correlates of knee pain in older adults, 264

fulminating hydralazine-induced lupus pneumonitis, 501

GCA, ¹⁸F-fluorodeoxyglucose PET in, 131 GCA, sustained spontaneous clinical remission in, 160

genital lupus, 821 infliximab-related lupus and associated valvulitis, 163

JIA, Sharp and Larsen scoring for assessment of radiographic progression in, 717 minocycline-induced cutaneous polyarteritis nodosa, 831

OA, clinical burden of radiographic hand OA, 636

OA, subchondral bone and, 493

pregnancy-related PM and massive perivillous fibrin deposition in the placenta, 154

pulmonary fibrosis in RA patient treated with adalimumab, 157 Immune system, inhibition of T cell costimulation as emerging therapeutic strategy for autoimmune rheumatic disease, 322 Improvement

feeling good rather than feeling better matters more to patients,

prospective validation of definition of improvement in pediatric SLE, 355, 990

Infection

RA, TNF inhibitor therapy and risk of serious postoperative orthopedic infection in, 333

septic arthritis caused by Abiotrophia defectiva, 976 Infliximab

AS, improved productivity and reduced workday loss, 569

AS, switching from infliximab to once-weekly etanercept in resistant or intolerant patients, 812

infliximab-related lupus and associated valvulitis, case report and literature review of, 163

pulmonary sarcoidosis during therapy with, 978

Infliximab (cont'd)

RA, anti-TNFα therapy for progression of subclinical atherosclerosis in, 150

Injection, knee arthritis, comparison of arthroscopic lavage plus corticosteroid administration, arthroscopic lavage plus placebo, and joint aspiration plus corticosteroid administration in, 964

Instrument validation

Cedars-Sinai Health-Related Quality of Life for Rheumatoid Arthritis instrument, development and validation of revision,

Edmonton Ankylosing Spondylitis Metrology Index, 575 PRINTO/ACR instrument for improvement in juvenile SLE,

Insurance, JRA, insurance status and disease outcome, 378 Internship and residency, availability of pediatric rheumatology training in US pediatric residencies, 836

Ischemia, GCA, involvement of intracranial arteries in, 985

Joint damage

JIA, Sharp and Larsen scoring for assessment of radiographic progression in, 717

RA, long-term impact of early treatment on radiographic progression of, 864

Joint laxity, knee OA, relationship between muscle strength and functional ability, 953

Joint pathology, multiple joint problems and daily living tasks in older adults, 757

Joint replacement

preoperative exercise and functional status for total hip and knee arthroplasty, 700

quality of life in, World Health Organization Quality of Life Short Version Instrument, 583

revision total knee replacement, expectations of recovery from,

total shoulder arthroplasty, trends in epidemiology of, 591 Joint sepsis, TNF inhibitor therapy and risk of serious postoper-

ative orthopedic infection in RA, 333

Joint tenderness, RA, social support, distress, and disability, 736 Juvenile arthritis, musculoskeletal screening examination (pGALS) for school-age children based on the adult GALS screen, 709

Juvenile Arthritis Quality of Life Questionnaire (JAQQ), healthrelated quality of life in adolescents with JIA, 199

Juvenile dermatomyositis, subcutaneous fat in, 564

Juvenile idiopathic arthritis (JIA)

correlation between activity and damage measures in early, advanced, and longstanding disease, 843

health-related quality of life in adolescents with, 199

pain intensity, level of agreement between children, parents, and physicians in rating of, 177

pain treatment, survey of rheumatologists, 81 parents as proxies of adolescents with, 189

perceived treatment adherence by children with JIA and their parents, 558

polyarticular childhood arthritis, fitness training and exercise testing in, 364

Sharp and Larsen scoring for assessment of radiographic progression in, 717

tool for early referral for chronic arthropathy, 373

Juvenile rheumatoid arthritis (JRA)

care of adult with, 208

insurance status and disease outcome, 378

tool for early referral for chronic arthropathy, 373

Knee

comparison of arthroscopic lavage plus corticosteroid administration, arthroscopic lavage plus placebo, and joint aspiration plus corticosteroid administration, 964 correlates of knee pain in older adults, 264

Knee (cont'd)

fracture risk correlated with knee pain and knee OA, 610 meniscectomy sequelae, muscle strength, functional performance, and self-reported outcomes, 946

multiple joint problems and daily living tasks in older adults, 757

OA, determinants of self efficacy for physical tasks, 94

OA, determining knee alignment, 306

OA, excess weight, pain, and mobility function transitions, 256 OA, feeling good rather than feeling better matters more to patients, 526

OA, functional status and pain, literature review, 779

OA, joint laxity and relationship between muscle strength and functional ability, 953

OA, pain medication and adherence to treatment in older adults, 272

OA, strength training and OA incidence and disease progres-

staging joint pain and disability, 411

Knee joint alignment, OA, alternative to full-leg radiograph for determining, 306

Knee replacement

preoperative exercise and functional status for total hip and knee arthroplasty, 700

quality of life in. World Health Organization Quality of Life Short Version Instrument, 583

revision total knee replacement, expectations of recovery from,

L

Latinos, health status, activity limitations, and disability in work and housework in arthritis patients, 442

Legislation, mandating coverage of biologic therapies for, 353 Limited cutaneous systemic sclerosis, influence of clinical features on health status, 473

Lipodystrophy, subcutaneous fat in juvenile DM, 564

Lower extremities

FM, pool exercise in waist-high warm water, health-related quality of life, and lower extremity strength, 66

OA, excess weight, pain, and mobility function transitions, 256 strength training and incidence and progression of knee OA, 690

etanercept-induced granulomas, 340

fulminating hydralazine-induced lupus pneumonitis, 501 pulmonary sarcoidosis during infliximab therapy, 978

RA, pulmonary fibrosis in patient treated with adalimumab, 157 SSc, forced vital capacity as predictor of pulmonary function decline, 598

Lupus. See Systemic lupus erythematosus

Lymphopenia, in SLE, association with clinical manifestations, serologic abnormalities, disease activity, and damage accrual,

Lymphoproliferative disease, EBV-associated B cell lymphoproliferative disease with NOMID, 823

Magnetic resonance spectroscopy, evaluation of CNS manifestations of SLE, 807

Massive perivillous fibrin deposition, in placenta, pregnancy-related PM and, 154

Measuring instruments. See also Questionnaires

ACR-SLE neuropsychological battery, 628

ANAM for computerized cognitive testing for SLE, 434

Bath Ankylosing Spondylitis Metrology Index (BASMI), 575 Cedars-Sinai Health-Related Quality of Life for Rheumatoid Arthritis instrument, 856

Child Adherence Report Questionnaire (CARQ), 558

Edmonton Ankylosing Spondylitis Metrology Index, 575

EuroQol-5D, 751

Health Education Impact Questionnaire (HEI-Q) to measure chronic disease self-management programs, 458

Measuring instruments. See also Questionnaires (cont'd)

Parent Adherence Report Questionnaire (PARQ), 558

Patient Acceptable Symptomatic State for AS, 960

RA, self-reporting instruments to assess RA, association between DAS28 and VAS general health, 745

Time Trade-Off, 751

World Health Organization Quality of Life Short Version Instrument for quality of life in hip and knee replacement, 583 Medicaid, JRA, insurance status and disease outcome, 378

Medical costs. See Cost assessment; Cost-effectiveness

Medical education, availability of pediatric rheumatology training in US pediatric residencies, 836

Minocycline, cutaneous polyarteritis nodosa induced by, 831 Minority groups. See Ethnicity

Mixed connective tissue disease (MCTD), cardiac tamponade in,

Mobility

AS, development and validation of Edmonton Ankylosing Spondylitis Metrology Index, 575

knee OA, determinants of self efficacy for physical tasks, 94 OA in lower extremities, excess weight, pain, and mobility function transitions, 256

Molecular biology, RANK ligand in normal and pathologic bone remodeling, potential for novel inhibitory molecules, 15 Monoclonal antibodies, RANK ligand in normal and pathologic

bone remodeling, potential for novel inhibitory molecules, 15 Mortality, short-term prediction of SLE mortality: classification of outcomes using random forests, 74

Muscles, skeletal muscle metabolism in patients with statin-induced adverse effects, 551

Muscle strength

FM, pool exercise in waist-high warm water and, 66

knee OA, joint laxity and relationship between muscle strength and functional ability, 953

meniscectomy and, muscle strength, functional performance, and self-reported outcomes 4 years after partial meniscectomy, 946

Musculoskeletal disorders, epidemiologic surveillance of upperextremity musculoskeletal disorders in working population,

Musculoskeletal screening, for school-age children based on the adult GALS screen, 709

Myocardial infarction, DMARDs and risk of, 531

Myositis-specific and myositis-associated antibodies, in idiopathic inflammatory myopathy, 791

Myotoxicity, skeletal muscle metabolism in patients with statininduced adverse effects, 551

Neonatal-onset multisystem inflammatory disease (NOMID), EBVassociated B cell lymphoproliferative disease with, 823

Neuropsychological functioning

SLE, behavioral correlates of the ACR-SLE battery, 628 SLE, CNS manifestations evaluated by magnetic resonance spectroscopy, 807

SLE, computerized cognitive testing, 434

Nonsteroidal antiinflammatory drugs (NSAIDs), cost-effectiveness of NSAID drug strategies, 338

Obesity, OA in lower extremities, excess weight, pain, and mobility function transitions, 256

Older adults

aging, arthritis, and disability, 175

comparison of perceived OA-related and aging-related health experiences, 905

correlates of knee pain in, 264

disability, population impact of arthritis on, 248 multiple joint problems and daily living tasks, 757

OA in lower extremities, excess weight, pain, and mobility function transitions, 256

Older adults (cont'd)

OA, pain medication and adherence to treatment in older adults, 272

OA, quality of care for community-dwelling older adults, 241 prescription opioid use for arthritis or low back pain, 35, 513 rofecoxib withdrawal, retrospective analysis of utilization patterns and cost implications among Canadian seniors, 27 staging joint pain and disability, 411

Opioids

for JIA, survey of rheumatologists, 81

prescription use among older adults with arthritis or low back pain, 35, 513

Osteoarthritis (OA)

aging, arthritis, and disability, 175

catastrophizing and pain in, 325

clinical burden of radiographic hand OA, 636

comparison of perceived OA-related and aging-related health experiences, 905

consequences of rehabilitation on disease progression and functional decline, 687

determining knee alignment in, 306

hip and knee, behavioral graded activity for, 925

hip and knee, correlates of knee pain in older adults, 264

hip and knee, functional status and pain, literature review of,

hip and knee, pain medication and adherence to treatment in older adults, 272

human retrovirus-4 proviral DNA in, 123

impact of diagnostic label of OA on perceptions of disability and willingness to help a parent, 913

knee, determinants of self efficacy for physical tasks, 94

knee, feeling good rather than feeling better matters more to patients, 526

knee, joint laxity and relationship between muscle strength and functional ability, 953

knee, risk of fracture correlated with knee pain and knee OA, 610

knee, staging joint pain and disability, 411

knee, strength training and OA incidence and disease progression, 690

lower extremities, excess weight, pain, and mobility function transitions, 256

pain medication and adherence to treatment in older adults,

preoperative exercise and functional status for total hip and knee arthroplasty, 700

prescription opioid use among older adults for arthritis and low back pain, 35, 513

psychometric evaluation of questionnaires, 480

quality of OA care for community-dwelling older adults, 241 rehabilitation for hip fracture: impact of OA on, 920

relationship satisfaction, illness uncertainty, partner caregiver burden and support, 86

revision total knee replacement, expectations of recovery from.

rofecoxib withdrawal, retrospective analysis of utilization patterns and cost implications among Canadian seniors, 27 subchondral bone and, 493

synovial fluid levels of anti-CCP antibodies and IgA RF in, 53,

Osteomyelitis, TNF inhibitor therapy and risk of serious postoperative orthopedic infection in RA, 333

Osteoporosis

care of adult with JRA, 208 care after fragility fracture, 724

care in a home health care setting, 971

management of in RA patient, 873

patient treatment preferences for, 729

Outcomes

AS, stability of the Patient Acceptable Symptomatic State over time in outcome criteria, 960

feeling good rather than feeling better matters more to patients,

health economic evaluation, primer for clinicians, 648

Outcomes (cont'd)

hip and knee replacement, quality of life after, 583

IIA, correlation between activity and damage measures in early, advanced, and longstanding disease, 843

JRA, insurance status and disease outcome, 378

knee OA, determinants of self efficacy for physical tasks, 94 measurement of chronic disease self-management programs,

meniscectomy and, muscle strength, functional performance, and self-reported outcomes 4 years after partial meniscec-

OA, behavioral graded activity for patients with OA of hip or

PM and DM, validity and reliability of Functional Index-2 as disease-specific measure of impairment, 114

profile of arthritis disability, 102

RA, self-reporting instruments to assess, association between DAS28 and VAS general health, 745

revision total knee replacement, expectations of recovery from,

SLE, short-term prediction of mortality, classification of outcomes using random forests, 74

Pain

arthritis and low back pain, prescription opioid use among older adults for, 35, 513

catastrophizing and pain in arthritis, FM, and other rheumatic diseases, 325

correlates of knee pain in older adults, 264

hip and knee OA, functional status and pain, literature review

JIA, level of agreement between children, parents, and physicians in rating pain intensity, 177

JIA, survey of rheumatologists on pain treatment, 81

JRA, insurance status and disease outcome, 378

knee pain, knee OA, and risk of fracture, 610

multiple joint problems and daily living tasks in older adults,

OA in lower extremities, excess weight, pain, and mobility function transitions, 256

OA, pain medication and adherence to treatment in older adults, 272

RA, social support, distress, and disability, 736

SLE, behavioral correlates of the ACR-SLE battery, 628

staging joint pain and disability, 411

Pain medication

arthritis and low back pain, prescription opioid use among older adults with, 35, 513

OA, pain medication and adherence to treatment in older adults, 272

Parent Adherence Report Questionnaire (PARQ), 558

JIA, level of agreement between children, parents, and physicians in rating pain intensity, 177

JIA, parents as proxies of adolescents with JIA, 189

JIA, perceived treatment adherence in children with JIA and their parents, 558

OA, impact of diagnostic label of OA on perceptions of disability and willingness to help a parent, 913

Patient Acceptable Symptomatic State, for AS, 960

Patient-doctor relationship

patients' preferences for decision making and feeling of being understood in medical encounter in RA patients, 878

trust in physicians in RA and SLE patients, 385 Patient satisfaction, rheumatology care in RA and AS, involvement in medical decisions, received information, satisfaction

with care, and unmet health care needs, 394 Patients. See also Patient-doctor relationship

feeling good rather than feeling better matters more to patients,

patients and professionals as research partners, 676

Patients. See also Patient-doctor relationship (cont'd)

preferences for decision making and feeling of being understood in medical encounter in RA patients, 878

rheumatology care in RA and AS, involvement in medical decisions, received information, satisfaction with care, and unmet health care needs, 394

treatment preferences for osteoporosis, 729

Pediatric rheumatology

availability of pediatric rheumatology training in US pediatric residencies, 836 status report, 833

Pediatric Rheumatology International Trials Organization (PRINTO), prospective validation of definition of improvement in juvenile SLE, 355, 990

Periaortitis, chronic periaortitis and HLA-DRB1*03, 126

Peripheral enthesopathies, epidemiologic surveillance of upperextremity musculoskeletal disorders in working population,

Physical activity. See also Exercise

using Internet technology to deliver a home-based physical activity intervention for RA patients, 935

Physical therapy, primary therapist model for RA rehabilitation, 42, 402

Physician-patient relationship. See Patient-doctor relationship Physicians. See Rheumatologists

Pneumonitis, fulminating hydralazine-induced lupus pneumoni-

Policy, mandating coverage of biologic therapies for, 353

Polyarteritis nodosa, minocycline-induced cutaneous polyarteritis nodosa, 831

Polyarticular childhood arthritis, fitness training and exercise testing in, 364

Polymyalgia rheumatica

editorial, 518

GCA, ¹⁸F-fluorodeoxyglucose PET in, 131

Polymyositis (PM)

Functional Index-2, validity and reliability of disease-specific measure of impairment, 114

perivillous fibrin deposition in placenta and pregnancy-related PM. 165

Positron emission tomography (PET), GCA, ¹⁸F-fluorodeoxyglucose PET in, 131

Predictors

revision total knee replacement, expectations of recovery from,

SLE, short-term prediction of mortality using classification of outcomes, 74

SSc, forced vital capacity as predictor of pulmonary function decline, 598

perivillous fibrin deposition in placenta and pregnancy-related PM, 165

RA, childbearing decisions and family size among women with RA, 217

Primary therapist model

cost-effectiveness in RA, 402

for RA rehabilitation, 42

Productivity

infliximab improves productivity and reduces workday loss in AS patients, 569

occupational hand use in persons with RA, 294

Psoriatic arthritis (PsA)

etanercept-induced granulomas, 340

synovial fluid levels of anti-CCP antibodies and IgA RF in, 53,

Psychological status. See also Coping; Relationships

illness intrusion and psychological adjustment to, social identity framework in 224

in SS and sicca symptoms without autoimmune features, 451 Pulmonary fibrosis, in RA patient treated with adalimumab, 157 Pulmonary function testing, SSc, forced vital capacity as predictor

of pulmonary function decline, 598

Q

Quadriceps, meniscectomy and, muscle strength, functional performance, and self-reported outcomes 4 years after partial meniscectomy, 946

Quality-adjusted life years, utility values, comparing Time Trade-Off and EuroQol, 751

Quality of care

OA, for community-dwelling older adults, 241 osteoporosis management in RA patients, 873

RA and AS, involvement in medical decisions, received information, satisfaction with care, and unmet health care needs, 394

RA, explicit process of care measurement, 884

Quality of life

comparison of perceived OA-related and aging-related health experiences, 905

FM and OA, relationship satisfaction in, 86

FM, pool exercise in waist-high warm water, health-related quality of life, and lower extremity strength, 66

JIA, parents as proxies of adolescents with, 189

psychologically meaningful activity, illness intrusiveness, and quality of life in rheumatic diseases, 172

RA, Cedars-Sinai Health-Related Quality of Life for Rheumatoid Arthritis instrument, development and validation of revision, 856

RA, effect of etanercept on fatigue, 287

SS and sicca symptoms without autoimmune features, 451 World Health Organization Quality of Life Short Version Instrument for quality of life in hip and knee replacement, 583 Ouestionnaires

musculoskeletal screening examination (pGALS) for school-age children based on the adult GALS screen, 709

OA questionnaires, psychometric evaluation of, 480

rheumatology care in RA and AS, involvement in medical decisions, received information, satisfaction with care, and unmet health care needs, 394

tool for early referral for chronic arthropathy, 373

R

Race, impact of diagnostic label of OA on perceptions of disability and willingness to help a parent, 913

Radiography

correlates of knee pain in older adults, 264

JIA. Sharp and Larsen scoring in assessment of radiographic progression in, 717

OA, alternative to full-leg radiograph for determination of, 306 OA, clinical burden of radiographic hand OA, 636

RA, long-term impact of early treatment on radiographic progression of, 864

Random forests, short-term prediction of SLE mortality, classifi-

cation of outcomes using, 74
RANK ligand, in normal and pathologic bone remodeling, poten-

tial for novel inhibitory molecules, 15 Recombinant human parathyroid hormone, patient treatment preferences for osteoporosis, 729

Recovery, revision total knee replacement, expectations of recovery from, 314

Referral

delays in suspected RA, 300

early referral for chronic arthropathy, 373

Rehabilitation

consequences of disease progression and functional decline, 687

hip fracture, impact of OA on rehabilitation for, 920 profile of arthritis disability, 102

RA, cost-effectiveness of primary therapist model in, 402 RA, primary therapist model for rehabilitation, 42

Relationships. See also Family; Psychological status patterns of illness-related interaction in couples coping with RA. 279

relationship satisfaction in FM and OA patients, 86 vasculitis in nagement and interpersonal processes, 670

Remission, GCA, sustained spontaneous clinical remission in, 160

Research

AC&R journal policies on authorship and disclosures, 345 patients and professionals as research partners, 676

Respiratory system, Churg-Strauss syndrome presenting with salivary gland enlargement and respiratory distress, 167 Response to therapy

feeling good rather than feeling better matters more to patients, 526

JIA, correlation between activity and damage measures in early, advanced, and longstanding disease, 843

PRINTO/ACR, prospective validation of definition of improvement in juvenile SLE, 355, 990

Rheumatic disease

ACR classification and response criteria for, 348, 992

illness intrusion and psychological adjustment to, social identity framework in, 224

inhibition of T cell costimulation as emerging the rapeutic strategy for autoimmune rheumatic disease, 322

mandating coverage of biologic therapies for, 353

psychologically meaningful activity, illness intrusiveness, and quality of life in, 172

Rheumatoid arthritis (RA)

anti-CCP and anti-Sa/citrullinated vimentin autoantibodies in, 657

anti-TNF α therapy for progression of subclinical atherosclerosis in, 150

Cedars-Sinai Health-Related Quality of Life for Rheumatoid Arthritis instrument, development and validation of revision, 856

childbearing decisions and family size among women with, 217 disability, social support, and distress in, 736

DMARDs and risk of acute myocardial infarction, 531

etanercept, effect on fatigue, 287

explicit process of care measurement applied to, 884

human retrovirus-4 proviral DNA in, 123

infliximab-related lupus and associated valvulitis, 163 Internet technology to deliver a home-based physical activity

Internet technology to deliver a home-based physical activity intervention for patients with, 935

long-term impact of early treatment on radiographic progression of, 864

occupational hand use in, 294

osteoporosis management in patients, 873

patients' preferences for decision making and feeling of being understood in medical encounter, 878

patterns of illness-related interaction in couples coping with, 279

prescription opioid use among older adults for arthritis and low back pain, 35, 513

primary therapist model, cost-effectiveness, 402

primary therapist model for rehabilitation, 42

pulmonary fibrosis during adalimumab therapy, 157

referral delays in suspected RA, 300

rheumatology care, involvement in medical decisions, received information, satisfaction with care, and unmet health care needs, 394

rofecoxib withdrawal, retrospective analysis of utilization patterns and cost implications among Canadian seniors, 27

self-reporting assessment instruments: association between DAS28 and VAS general health, 745

synovial fluid levels of anti-CCP antibodies and IgA RF in, 53, 681

TNF inhibitor therapy and risk of serious postoperative orthopedic infection in, 333

trust in physicians by patients with, 385

utility values and quality-adjusted life years: comparing Time Trade-Off and EuroQol, 751

Rheumatoid factor (RF), IgA RF synovial fluid levels in RA, PsA, and OA, 53, 681

Rheumatologists. See also Patient-doctor relationship economic evaluation, primer for clinicians, 648

JIA, level of agreement between children, parents, and physicians in rating pain intensity, 177

Rheumatologists. See also Patient-doctor relationship (cont'd)

JIA, survey of rheumatologists on pain treatment, 81

JRA, care of adult with, 208

patients and professionals as research partners, 676

referral delays in suspected RA, 300

rheumatologist's perspective on musculoskeletal ultrasound, 341, 342, 343

scleroderma treatment differences between experts and general rheumatologists, 138

trust in physicians in RA and SLE patients, 385

what are we trying to do?, 515

Rheumatology

availability of pediatric rheumatology training in US pediatric residencies, 836

patients and professionals as research partners, 676 pediatric rheumatology, status report, 833

Risk factors

DMARDs and risk of acute myocardial infarction, 531 fracture risk correlated with knee pain and knee OA, 610 glucocorticoids and risk of tuberculosis, 1, 19

RA, TNF inhibitor therapy and risk of serious postoperative orthopedic infection, 333

SLE, risk factors for cardiovascular disease, 892

Rofecoxib, impact of withdrawal, retrospective analysis of utilization patterns and cost implications among Canadian seniors, 27

Rotator cuff syndrome, feeling good rather than feeling better matters more to patients, 526

S

Salivary glands

Churg-Strauss syndrome presenting with salivary gland enlargement and respiratory distress, 167

diffuse infiltrative lymphocytosis syndrome, 466 SAPS, quality of life and psychological status in, 451

Sarcoidosis

development of during etanercept therapy, 817 pulmonary sarcoidosis during infliximab therapy, 978

Scales. See Measuring instruments Scleroderma. See Systemic sclerosis

Scoring, See also Assessment; Measuring instruments

JIA, Sharp and Larsen scoring for assessment of radiographic progression in, 717

Screening examination, musculoskeletal screening examination (pGALS) for school-age children based on the adult GALS screen, 709

Self-efficacy, knee OA, determinants of self efficacy for physical tasks, 94

Self-management, measurement of chronic disease self-management programs, 458

Septic arthritis, caused by Abiotrophia defectiva, 976

Serologically active clinically quiescent patients, SLE, association of antinucleosome antibodies with disease flare in, 900

Service models primary therapist model for RA, cost-effectiveness in, 402 primary therapist model for RA rehabilitation, 42

houlder epidemiologic surveillance of upper-extremity musculoskeletal

disorders in working population, 765
trends in epidemiology of total shoulder arthroplasty, 591
Sicca asthenia polyaloja syndrome (SAPS), quality of life and

Sicca asthenia polyalgia syndrome (SAPS), quality of life and psychological status, 451

Sjögren's syndrome (SS)

diffuse infiltrative lymphocytosis syndrome, 466 quality of life and psychological status, 451

Skin

durometry for assessment of skin disease in SSc, 603 SAPHO and SpA, 665

Social roles, illness intrusion and psychological adjustment to: social identity framework in, 224

Social support, RA, distress, and disability, 736

Socioeconomic status, JRA, insurance status and disease outcome, 378

Spinal mobility, AS, development and validation of Edmonton Ankylosing Spondylitis Metrology Index, 575

Spondylarthropathy (SpA) and collagenous colitis, 507

SAPHO and SpA, 665

Statins, skeletal muscle metabolism in patients with statin-induced adverse effects, 551

Stem cell transplantation, update on adult stem cell therapy in autoimmune diseases, 521

Strength

FM, pool exercise in waist-high warm water, health-related quality of life, and lower extremity strength, 66

OA, determinants of self efficacy for physical tasks, 94 Strength training, incidence and progression of knee OA and, 690 Stress, SLE, coping skills and health-related quality of life, 427 Subchondral bone, OA and, 493

Synovial fluid, anti-CCP antibodies and IgA RF synovial fluid levels in RA, PsA, and OA, 53, 681

Synovitis

care of adult with JRA, 208

SAPHO, SpA and, 665

Systemic lupus erythematosus (SLE)

antinucleosome antibodies association with disease flare, 900 behavioral correlates of the ACR-SLE battery, 628

CNS manifestations evaluated by magnetic resonance spectroscopy, 807

computerized cognitive testing for, 434

coping skills and health-related quality of life, 427

cost of treatment of childhood-onset SLE, 184

fulminating hydralazine-induced lupus pneumonitis, 501 genital lupus, 821 infliximab-related lupus and associated valvulitis, 163

juvenile SLE, PRINTO/ACR for response to therapy for, 355,

lymphopenia, association with clinical manifestations, serologic abnormalities, disease activity, and damage accrual, 799 risk factors for cardiovascular disease in, 892

serologically active clinically quiescent patients, association of antinucleosome antibodies with disease flare in, 900

short-term prediction of mortality, classification of outcomes using random forests, 74

trust in physicians by patients, 385

Systemic sclerosis (SSc)

classification criteria for, 348, 992

durometry for assessment of skin disease in, 603

forced vital capacity as predictor of pulmonary function decline, 598

health status in patients with limited cutaneous SSc, 473 treatment differences between experts and general rheumatologists, 138

T

T cell costimulation, inhibition of as emerging therapeutic strategy for autoimmune disease, 322

Thromboembolism, as complication of ANCA-associated vasculitis, 146

Thrombophilia, APS and recurrent thrombosis in children, 850 Time Trade-Off, utility values and quality-adjusted life years, comparing with EuroQol, 751

Total joint replacement. See Joint replacement

Treatment adherence

OA, pain medication and adherence to treatment in older adults with, 272

perceived treatment adherence in children with JIA and their parents, 558

training diaries and, 662

Tuberculosis, glucocorticoids and risk of, 1, 19

Tumor necrosis factor (TNF) inhibitor, RA, TNF inhibitor therapy and risk of serious postoperative orthopedic infection in, 333

ı

Ultrasonography, rheumatologist's perspective on musculoskeletal ultrasound in rheumatology, 341, 342, 343 Upper extremities, musculoskeletal disorders in working population, 765

Urate-lowering therapy, serum urate levels to determine the period free of gouty symptoms after withdrawal of therapy, 786

V

Valvulitis, infliximab-related lupus and associated valvulitis: case report and literature review of, 163

Vasculitis

GCA, involvement of intracranial arteries in, 985 interpersonal processes and management of, 670

thromboembolic events as complication of ANCA-associated vasculitis, 146

Visual Analog Scale (VAS), RA, self-reporting instruments to assess RA, association between DAS28 and VAS general health, 745

W

Women

FM, pool exercise in waist-high warm water, health-related quality of life, and lower extremity strength, 66 perivillous fibrin deposition in placenta and pregnancy-related

PM, 165

preoperative exercise and functional status for total hip and knee arthroplasty, 700 RA, childbearing decisions and family size among women with,

217

Work disability arthritis-work spillover among employed adults, 233

health status, activity limitations, and disability in work and housework in Latino and non-Latino arthritis patients, 442 occupational hand use in persons with RA, 294

World Health Organization Quality of Life Short Version Instrument, for hip and knee replacement, 583

Wrist, epidemiologic surveillance of upper-extremity musculoskeletal disorders in working population, 765